# Chapter 104: Other Hallucinogen Use Disorder

## Biological and Neurological Basis of Other Hallucinogen Use Disorder

### Introduction

Other Hallucinogen Use Disorder represents a complex and multifaceted psychiatric condition characterized by a maladaptive pattern of using a class of psychoactive substances that produce significant alterations in perception, mood, and thought (Pechnick et al., 2014; Rastegar, 2020). This category includes a diverse array of natural and synthetic compounds, such as d-lysergic acid diethylamide (LSD), psilocybin, mescaline, and various "designer drugs" like 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) and dissociative anesthetics like phencyclidine (PCP) and ketamine (Pechnick et al., 2014; Smith et al., 2002; Rastegar & Fingerhood, 2015). The disorder is defined not merely by use, but by a pattern leading to clinically significant impairment or distress, manifesting in symptoms such as a persistent desire to use, tolerance, withdrawal, and continued use despite negative consequences to social, occupational, or personal functioning (Franklin, 1995; Wakefield, 2015; Perera-Diltz, 2015).

While the subjective experiences induced by hallucinogens—ranging from euphoria and altered sensory perception to anxiety, paranoia, and psychosis—have been documented for decades, the underlying biological and neurological mechanisms that drive the transition from recreational use to a compulsive, addictive disorder are still being elucidated (Cole & Katz, 1964; Snyder, 2019). Addiction is increasingly understood as a chronic, relapsing brain disease, rooted in the disruption of neural circuits that regulate reward, motivation, memory, and executive control (Koob, 2020; Ivlieva, 2011; Smith, 2022). The development of dependence on any substance, including hallucinogens, involves a complex interplay of genetic vulnerability, environmental factors, and drug-induced neuroplastic changes that progressively alter brain structure and function (Winters & Ingwalson, 2022; Scuvée‐Moreau, 2013).

This chapter aims to provide a comprehensive overview of the biological and neurological basis of Other Hallucinogen Use Disorder, drawing exclusively upon a defined body of scientific literature. We will explore the critical roles of various neurotransmitter systems, the specific brain regions and neural circuits implicated in the disorder, and the genetic and molecular factors that may confer vulnerability. Furthermore, we will examine neuroimaging findings, the impact of these substances on the developing brain, and the neuroplastic changes that underpin the progression of the disorder. Finally, we will consider the biological rationale for potential treatment interventions and highlight areas where future research is critically needed to advance our understanding and management of this challenging condition.

### Neurobiological Systems

The transition from voluntary drug use to the compulsive drug-seeking and drug-taking behavior that characterizes addiction is underpinned by profound neuroadaptations in the brain (Vanderschuren, 2008; Koob, 2020). While hallucinogens are a heterogeneous class of drugs with diverse primary pharmacological targets, their capacity to induce a substance use disorder suggests they ultimately converge on common neurobiological pathways involved in reward, motivation, and cognitive control (Ivlieva, 2011; Scuvée‐Moreau, 2013). The development of Other Hallucinogen Use Disorder can be conceptualized as a three-stage cycle involving binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation, each associated with distinct neurocircuitry (Koob, 2014).

**Neurotransmitter Systems and Neuropharmacology**

The subjective and addictive effects of hallucinogens are mediated by their interactions with several key neurotransmitter systems. These substances can be broadly categorized by their primary pharmacological mechanisms, which helps to explain their distinct clinical profiles and abuse potential (Pechnick et al., 2014; Rastegar, 2020).

*   **The Serotonin (5-HT) System:** The classic or "serotonergic" hallucinogens, such as LSD, psilocybin, and mescaline, exert their primary effects through the serotonin system (Pechnick et al., 2014). Their psychoactive properties, including profound alterations in perception and thought, are largely attributed to their agonist or partial agonist activity at serotonin 5-HT2A receptors (Latt et al., 2009; Boren & Boren, 2019). The stimulation of these receptors, particularly in cortical and hippocampal regions, is believed to be fundamental to the hallucinogenic experience (Latt et al., 2009). The drug MDMA ("ecstasy") also has a powerful effect on the serotonin system, but through a different mechanism; it binds to the serotonin transporter, causing a massive release and subsequent depletion of serotonin from presynaptic terminals (Patel et al., 2011; Molero‐Chamizo, 2005). This surge of serotonin contributes to its desired effects of euphoria and empathy, but chronic use can lead to long-term serotonergic damage (Colado et al., 2007; Chummun et al., 2010). The interaction of these drugs with other serotonergic medications, such as antidepressants, can be dangerous, potentially leading to a life-threatening condition known as serotonin syndrome, characterized by autonomic hyperactivity, neuromuscular abnormalities, and mental status changes (Scotton et al., 2019; Yates et al., 2011).

*   **The Dopamine (DA) System:** The brain's mesocorticolimbic dopamine system is considered a "common neural currency" for reward and is fundamentally involved in the reinforcing effects of most drugs of abuse (Ivlieva, 2011; Scuvée‐Moreau, 2013). This system, which includes projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and prefrontal cortex (PFC), mediates incentive salience and motivation (Koob, 2020; Tyler & Leggio, 2024). Hallucinogens with stimulant properties, such as MDMA and synthetic cathinones ("bath salts"), directly increase synaptic dopamine levels, contributing to their high abuse potential and addictive properties (Graddy & Rastegar, 2020; Krishnan, 2024). This dopaminergic action is similar to that of cocaine and amphetamines (Snyder, 2019; Antonio & Alfredo, 2012). Even classic hallucinogens, while primarily serotonergic, indirectly modulate the dopamine system, which is crucial for the development of drug-seeking behaviors and addiction (Wise, 1982; Kalivas, 2003). Chronic drug exposure leads to neuroadaptive changes in this system, contributing to tolerance, craving, and the compulsive drug use seen in addiction (Kalivas, 2003; Robinson, 2014). This dysregulation can manifest as a dopamine dysregulation syndrome, a form of addictive behavior characterized by an overwhelming need to engage in the rewarding activity (Djamshidian et al., 2022).

*   **The Glutamate System:** Dissociative hallucinogens, such as PCP and ketamine, produce their unique effects by acting as noncompetitive antagonists at the N-methyl-D-aspartate (NMDA) receptor, a key component of the glutamate system (Rastegar, 2020; Kalsi et al., 2011). Glutamate is the brain's primary excitatory neurotransmitter, and its modulation by these drugs leads to the characteristic dissociative state, with amnesia, analgesia, and profound perceptual distortions (Jansen, 1990; Smith et al., 2002). Beyond the acute effects of dissociatives, the glutamate system is critically involved in the broader neurobiology of addiction. Chronic exposure to various drugs of abuse, including alcohol and cocaine, leads to significant glutamatergic plasticity, particularly in the circuitry connecting the PFC and the NAc (Quintero Garzola, 2013). These changes are thought to underlie craving and relapse, as dysregulation of glutamate homeostasis can heighten responses to drug-related cues (Becker & Redmond, 2002; Quintero Garzola, 2013).

*   **The GABA System:** Gamma-aminobutyric acid (GABA) is the brain's primary inhibitory neurotransmitter. Some "club drugs," such as gamma-hydroxybutyrate (GHB), exert their sedative and euphoric effects by acting on GABAergic systems (Galloway et al., 1997; Mattison & Cherner, 2005). Chronic use of GHB can lead to physical dependence and a severe withdrawal syndrome characterized by insomnia, anxiety, and tremor (Galloway et al., 1997; Moitroux & Kestens, 2023). Furthermore, benzodiazepines, which are positive allosteric modulators of the GABAA receptor, are frequently used to manage the acute agitation, anxiety, or seizures that can occur with hallucinogen intoxication (García Fraga & Mayán Conesa, 2006; Erstad & Cotugno, 1995; Bismuth et al., 1980). This highlights the role of the GABA system in both the effects of certain hallucinogenic substances and the clinical management of their adverse consequences.

**Brain Regions, Neural Circuits, and Functional Connectivity**

Hallucinogen Use Disorder arises from drug-induced alterations in distributed neural circuits that govern emotion, cognition, and behavior. While different hallucinogens have distinct initial targets, their chronic use is thought to hijack and dysregulate core brain networks associated with addiction.

*   **The Mesocorticolimbic Reward Pathway:** This circuit, comprising the VTA, NAc, and PFC, is central to processing reward and motivation and is a primary target for all addictive drugs (Ivlieva, 2011; Tyler & Leggio, 2024). Acute administration of reinforcing drugs, including many hallucinogens, increases dopamine release in the NAc, producing feelings of euphoria and pleasure that drive initial use (Scuvée‐Moreau, 2013; Hurd, 1996). With repeated use, this circuit undergoes neuroplastic changes. The brain begins to attribute an exaggerated "incentive salience" to the drug and its associated cues, leading to intense craving and motivational drive to seek the drug (Kalivas, 2003; Robinson, 2014). This process, termed sensitization, can persist for months or years after drug cessation and is a key contributor to relapse (Robinson, 2014; Stewart, 2003).

*   **The Extended Amygdala and Stress Circuits:** This system, which includes the central nucleus of the amygdala, the bed nucleus of the stria terminalis, and a portion of the NAc, is critically involved in processing negative emotional states and the brain's response to stress (Koob, 2020). In the addiction cycle, this circuit becomes hyperactive during withdrawal, producing the negative affective states of dysphoria, anxiety, and irritability (hyperkatifeia) that characterize abstinence (Koob, 2020; Vendruscolo & Koob, 2019). This negative emotional state becomes a powerful motivator for relapse, as the individual seeks the drug not for pleasure (positive reinforcement) but to alleviate distress (negative reinforcement) (Koob, 2020; Ashok, 2017). Stress itself is a potent trigger for relapse, and its effects are mediated through this circuitry, involving neurochemicals like corticotropin-releasing factor (CRF) (Wand, 2008; Koob, 2020).

*   **The Prefrontal Cortex and Executive Control Circuits:** The PFC is responsible for executive functions such as decision-making, impulse control, and assigning value to outcomes (Wheeler, 2014). In addiction, there is a functional shift from PFC-driven, goal-directed behavior to more automatic, habit-driven responses controlled by the striatum (Ivlieva, 2011). Chronic drug use impairs PFC function, leading to the core symptom of "loss of control" over drug intake (Vanderschuren, 2008; Quintero Garzola, 2013). This impairment compromises an individual's ability to weigh the long-term negative consequences of drug use against the immediate gratification, contributing to compulsive drug-seeking despite adverse outcomes (Bari et al., 2010; Reed & Naudé, 2020).

*   **The Hippocampus and Amygdala: Memory and Conditioning:** The hippocampus and amygdala are crucial for learning and memory, particularly for associating environmental cues with rewarding or aversive experiences (Müller, 2013). In the context of addiction, these structures mediate the powerful conditioning processes whereby neutral stimuli (e.g., places, people, paraphernalia) become associated with drug use (Ivlieva, 2011; Müller, 2013). Subsequent exposure to these cues can trigger intense craving and relapse, even after long periods of abstinence (Daley & Douaihy, 2019; Stewart, 2003). This drug-associated learning is a form of aberrant, long-lasting memory that contributes significantly to the chronic, relapsing nature of the disorder (Müller, 2013; Kalivas et al., 2003).

### Genetic and Molecular Basis

The development of Other Hallucinogen Use Disorder, like other substance use disorders (SUDs), is not solely a function of drug exposure but results from a complex interaction between the drug, the environment, and an individual's biological vulnerability (Winters & Ingwalson, 2022; Smith et al., 2008). Genetic factors play a significant role in determining this vulnerability, influencing everything from initial drug response to the propensity for developing compulsive use (Hechtman, 1991; Modigh et al., 1998).

**Genetic Factors and Heritability**

While specific genes for hallucinogen use disorder are not detailed in the provided literature, it is well-established that SUDs in general have a substantial heritable component (Zoorob et al., 2018; Smith et al., 2008). Heritability estimates for alcohol use disorder, for instance, range from 40% to 60%, indicating that a significant portion of the risk is genetic (Smith et al., 2008; DiMartini, 2007). This predisposition is considered polygenic, meaning it involves many genes with small, additive effects rather than a single "addiction gene" (Ivlieva, 2011; Smith et al., 2008).

Genetic vulnerability can manifest in several ways. Some individuals may have a genetic predisposition to certain personality traits, such as high novelty-seeking or impulsivity, which are associated with an increased risk of substance use and the development of SUDs (Voon et al., 2007; Bari et al., 2010). There may also be inherited differences in how an individual's brain responds to a drug's effects, influencing whether the initial experience is perceived as intensely pleasurable and reinforcing (Radhakrishnan et al., 2014; Batta & Farid, 2011). For example, genetic variations in dopamine or serotonin receptor genes could alter an individual's sensitivity to the rewarding or psychotomimetic effects of hallucinogens (Radhakrishnan et al., 2014; Gram et al., 1993). A family history of substance use disorders is a consistent and powerful risk factor, reflecting this shared genetic and environmental vulnerability (DiMartini, 2007; Batta & Farid, 2011).

**Molecular and Cellular Mechanisms**

At the molecular level, the transition to addiction is a form of drug-induced, long-term neural plasticity (Vanderschuren, 2008; Antonio & Alfredo, 2012). Chronic exposure to hallucinogens, like other drugs of abuse, triggers a cascade of cellular and molecular adaptations within the neural circuits previously described. These enduring changes are what transform voluntary drug use into a compulsive disorder (Scuvée‐Moreau, 2013).

Key molecular mechanisms include:

*   **Changes in Gene Expression:** Repeated drug administration leads to lasting changes in gene expression within neurons of the reward and stress pathways (Kalivas et al., 2003; Antonio & Alfredo, 2012). For example, the transcription factor ΔFosB has been identified as a critical molecular switch that accumulates in NAc neurons with chronic drug exposure and is thought to mediate long-term changes that contribute to sensitization and relapse vulnerability (Antonio & Alfredo, 2012).
*   **Receptor Dysregulation:** The brain attempts to counteract the persistent overstimulation from drugs by altering its receptor systems. This can involve the downregulation (a decrease in the number or sensitivity) of receptors that are chronically stimulated, which contributes to the phenomenon of tolerance, where higher doses of the drug are needed to achieve the same effect (Trujillo, 2002; Tyler & Leggio, 2024). Conversely, withdrawal can be associated with an upregulation or hypersensitivity of opposing systems, contributing to the negative affective state (Becker, 1998; Koob, 2020). For example, chronic blockade of NMDA receptors by ketamine may lead to an upregulation of these receptors, potentially contributing to withdrawal phenomena.
*   **Synaptic Plasticity:** Addiction is fundamentally a disorder of learning and memory (Müller, 2013; Ivlieva, 2011). Drugs of abuse usurp the molecular mechanisms of synaptic plasticity, such as long-term potentiation (LTP) and long-term depression (LTD), that normally underlie the formation of memories for natural rewards. In particular, alterations in glutamatergic signaling at synapses in the VTA, NAc, and PFC are believed to strengthen the neural connections that drive drug-seeking behavior (Quintero Garzola, 2013). Changes in dendritic spine morphology and density in these regions provide a structural correlate for these lasting synaptic changes (Quintero Garzola, 2013).
*   **Epigenetic Modifications:** Environmental factors, including drug use and stress, can cause epigenetic changes, such as DNA methylation, which alter gene expression without changing the DNA sequence itself (Sussman, 2025). These modifications may represent a mechanism by which life experiences, particularly early life adversity, can "get under the skin" to increase long-term vulnerability to addiction by altering the function of genes involved in stress and reward pathways (Ferrara, 2014; Johnson & Buisman‐Pijlman, 2016).

### Brain Structure and Function

The study of structural and functional brain abnormalities provides a critical window into the neuropathology of Other Hallucinogen Use Disorder. While much of the foundational work has been done with other substances of abuse, the available literature suggests that chronic hallucinogen use is also associated with significant and potentially lasting changes in the brain's architecture and activity.

**Neuroimaging Findings**

Neuroimaging techniques offer non-invasive methods to investigate the living human brain, revealing alterations in both structure and function associated with chronic drug use. The provided literature, however, offers limited specific data on hallucinogen use disorder, often requiring cautious extrapolation from findings related to other substances, particularly cannabis and MDMA.

*   **Structural Changes:** Chronic use of some psychoactive substances has been linked to changes in brain volume. For instance, studies on regular cannabis users have reported a dose-dependent decrease in the density of gray matter in key limbic regions such as the hippocampus and amygdala (Dervaux, 2013). Given the role of these structures in memory and emotional regulation, such changes could contribute to the cognitive and affective disturbances seen in SUDs. Chronic abuse of stimulants like amphetamines and cocaine has also been associated with cerebral atrophy (Barroso Moguel et al., 1993; Ornoy, 2002). Some research suggests that MDMA may cause long-term damage to serotonin neurons, which could have structural correlates, though this remains an area of active investigation (Colado et al., 2007). It is crucial to acknowledge that the provided sources do not contain detailed structural MRI studies specifically on classic hallucinogen use disorder, representing a significant gap in the literature.

*   **Functional Changes:** Functional neuroimaging studies, which measure brain activity, have provided insights into the dysregulated neural circuits in addiction. A consistent finding across various SUDs is altered activity within the mesocorticolimbic reward pathway (Ivlieva, 2011). In individuals with addiction, exposure to drug-related cues elicits robust activation in brain regions like the NAc, amygdala, and PFC, which correlates with subjective craving (Daley & Douaihy, 2019; Franken & Wiers, 2013). This hypersensitivity to drug cues is a hallmark of the addicted brain (Robinson, 2014). Concurrently, these individuals often show a blunted response to natural rewards, reflecting an anhedonic state that may perpetuate drug use (Wise, 1982). Furthermore, studies consistently show hypofrontality, or reduced baseline activity in the PFC, in individuals with SUDs (Majewska, 1996). This PFC dysfunction is thought to underlie the impairments in executive control, decision-making, and impulse regulation that are central to the loss of control over drug use (Koob, 2020; Vanderschuren, 2008).

**Neuropsychological and Cognitive Impairment**

Chronic use of hallucinogens is associated with a range of cognitive deficits that reflect the underlying neural dysfunction. These impairments can persist even during periods of abstinence and contribute significantly to functional disability (Pechnick et al., 2014; Rastegar, 2020).

*   **Memory and Learning:** Memory impairment is a frequently reported consequence of chronic hallucinogen use. Both classic hallucinogens like cannabis and dissociatives like ketamine have been shown to acutely and chronically impair memory processes (Karila et al., 2014; Jansen, 1990; Foo et al., 2012). For example, chronic cannabis use is associated with deficits in attention, working memory, and episodic memory (Dervaux, 2013; Karila et al., 2014; Ornoy, 2002). Similarly, long-term ketamine users have described impaired recall and attention that persists after cessation of use (Jansen, 1990). These deficits are likely linked to dysfunction in the hippocampus and PFC, brain regions rich in cannabinoid and NMDA receptors, respectively (Dervaux, 2013).

*   **Executive Function:** As suggested by functional imaging findings of hypofrontality, executive dysfunction is a core feature of SUDs. Individuals with hallucinogen use disorder may exhibit difficulties with planning, cognitive flexibility, decision-making, and impulse control (Majewska, 1996; Bari et al., 2010). These deficits can manifest as poor judgment, risk-taking behavior, and an inability to inhibit the prepotent urge to seek and use drugs, despite awareness of negative consequences (Reed & Naudé, 2020; Vanderschuren, 2008).

*   **Attention and Psychomotor Performance:** Acute intoxication with many hallucinogens, including cannabis, MDMA, and PCP, impairs attention, concentration, and psychomotor coordination (Karila et al., 2014; Logan & Couper, 2003; Burns et al., 1975). These effects create significant risks, particularly in situations requiring vigilance, such as driving (Logan & Couper, 2003). While some of these deficits may resolve with abstinence, evidence suggests that chronic, heavy use, especially when initiated during adolescence, can lead to more persistent attentional problems (Karila et al., 2014; Ornoy, 2002; Hyytiä, 2015).

It is important to note that the relationship between hallucinogen use and cognitive impairment is complex. Pre-existing cognitive deficits or psychiatric conditions may increase vulnerability to both substance use and its negative consequences (Majewska, 1996). Furthermore, the use of multiple substances, a common pattern among individuals with hallucinogen use disorder, can make it difficult to attribute specific deficits to a single agent (Kosten, 1991; Miller & Gold, 1990).

### Developmental Neurobiology

The trajectory of Other Hallucinogen Use Disorder is profoundly influenced by developmental factors, with adolescence emerging as a period of heightened vulnerability to the initiation of substance use and the subsequent development of addiction (Winters & Ingwalson, 2022; Vignau & Karila, 2003). The adolescent brain is not merely a smaller version of the adult brain; it is undergoing dynamic and critical maturational processes that can be disrupted by exposure to psychoactive substances (Hyytiä, 2015).

**Adolescence as a Critical Period of Vulnerability**

Adolescence is characterized by significant neurodevelopmental changes, particularly within the prefrontal cortex and the mesocorticolimbic dopamine system (Dervaux, 2013; Hyytiä, 2015). The PFC, which governs executive functions like impulse control, decision-making, and risk assessment, is one of the last brain regions to fully mature, a process that continues into the early twenties (Schweren, 2016). Simultaneously, the dopamine-driven reward system is particularly active and sensitive during this period, leading to heightened novelty-seeking, risk-taking, and susceptibility to peer influence (Bari et al., 2010; Winters & Ingwalson, 2022).

This neurodevelopmental imbalance—a highly reactive reward system coupled with an immature executive control system—creates a "perfect storm" for the initiation of substance use (López‐Caneda et al., 2013). Adolescents are biologically primed to seek out novel and rewarding experiences, while their capacity to fully appreciate long-term consequences and inhibit impulsive behaviors is not yet fully developed (Schwartz, 1984; Reed & Naudé, 2020). Consequently, early initiation of substance use, including hallucinogens, is a robust predictor of developing a substance use disorder later in life (Radhakrishnan et al., 2014; Modigh et al., 1998). The earlier the age of first use, the greater the risk for addiction and other adverse outcomes (Vignau & Karila, 2003; Forray, 2016).

**Neurotoxic Effects on the Developing Brain**

Exposure to hallucinogens and other drugs of abuse during the critical window of adolescent brain development can interfere with normal maturational processes, potentially leading to lasting structural and functional abnormalities (Hyytiä, 2015; Dervaux, 2013). For example, chronic cannabis use during adolescence has been associated with alterations in brain structure, including reduced integrity of white matter tracts and changes in gray matter volume in regions like the hippocampus (Dervaux, 2013; Hyytiä, 2015). These structural changes may underlie the persistent cognitive deficits in attention, memory, and executive function observed in adults who were heavy adolescent users (Ornoy, 2002; Karila et al., 2014).

Because the endocannabinoid system plays a crucial role in synaptic pruning and brain maturation during adolescence, its disruption by exogenous cannabinoids like THC can have particularly detrimental effects (Dervaux, 2013). Similarly, drugs that affect the serotonin and dopamine systems, such as MDMA and other stimulants, can interfere with the development of these vital neurotransmitter systems (Colado et al., 2007). While some drug-induced changes may be reversible with prolonged abstinence, the impact on an individual's functional capacity and life trajectory, including educational and occupational achievement, can be significant and long-lasting (Hyytiä, 2015; Catheline, 2005).

**Role of Early Life Stress and Trauma**

A substantial body of evidence indicates that adverse childhood experiences, such as physical, sexual, or emotional abuse, neglect, or significant family dysfunction, are powerful risk factors for the development of substance use disorders in adolescence and adulthood (Winters & Ingwalson, 2022; Ferrara, 2014; Batta & Farid, 2011). Early life stress can have profound and enduring effects on the development of brain circuits that regulate stress, emotion, and reward (Johnson & Buisman‐Pijlman, 2016; Stratakis et al., 1995).

Chronic stress during development can lead to long-term dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and other stress-response systems (Wand, 2008; Anisman & Merali, 1999). This can result in a heightened vulnerability to the rewarding effects of drugs and an impaired ability to cope with future stressors, increasing the likelihood that an individual will turn to substances as a form of self-medication for underlying anxiety or depression (Khantzian, 1990; Anisman & Merali, 1999). Therefore, a history of childhood trauma not only increases the risk of initiating substance use but also complicates the course and treatment of an established SUD (Sher, 2015; Ferrara, 2014).

### Treatment Mechanisms

Understanding the biological basis of Other Hallucinogen Use Disorder is crucial for developing and refining treatment strategies. While psychosocial interventions remain a cornerstone of addiction treatment, pharmacological approaches aim to target the underlying neurobiological dysregulations that drive compulsive drug use and relapse (Rao & Kumar, 2008; Saunders et al., 2001). The provided literature points to several biological mechanisms through which treatments can be conceptualized, even if specific, approved medications for hallucinogen use disorder are lacking (Rastegar, 2020).

**Management of Acute Intoxication and Psychosis**

Acute intoxication with hallucinogens can present as a psychiatric emergency, often characterized by agitation, anxiety, paranoia, or frank psychosis (Pechnick et al., 2014; Benyamina et al., 2003). The primary biological goal of treatment in this phase is to restore neurochemical balance and ensure patient safety.

*   **Benzodiazepines:** These drugs, which enhance the inhibitory effects of the GABAergic system, are frequently used as first-line agents to manage agitation, anxiety, and seizures associated with hallucinogen intoxication (García Fraga & Mayán Conesa, 2006; Erstad & Cotugno, 1995). By increasing GABAergic tone, benzodiazepines can counteract the CNS hyperexcitability induced by stimulant or psychedelic hallucinogens (Bismuth et al., 1980; Adès & Lejoyeux, 1993).
*   **Antipsychotics:** When psychotic symptoms such as delusions and hallucinations are prominent and severe, or when agitation is not controlled by benzodiazepines, antipsychotic medications may be necessary (Dore & Sweeting, 2006; Buckley, 1999). These drugs primarily act by blocking dopamine D2 receptors, thereby reducing the excessive dopaminergic activity thought to underlie psychosis (Miller, 2007; Siris, 1978). Atypical antipsychotics, which also have significant effects on serotonin 5-HT2A receptors, may be particularly useful for psychoses induced by serotonergic hallucinogens (Siris, 1978; Buckley, 1999). However, their use requires caution, as they can have significant side effects and may interact with the abused substance (Lutz, 1976).

**Management of Withdrawal Syndromes**

While classic hallucinogens like LSD are not typically associated with a significant physical withdrawal syndrome, chronic use of other substances in this class, such as GHB or high-dose ketamine, can lead to dependence and a clinically significant withdrawal state upon cessation (Galloway et al., 1997; Kalsi et al., 2011). Furthermore, withdrawal from stimulant-like drugs such as MDMA can involve dysphoria, fatigue, and agitation (Graddy & Rastegar, 2020). The biological goal is to manage this withdrawal state to prevent severe complications and facilitate the transition to abstinence.

The management often involves a tapering strategy or substitution with a long-acting agent from the same pharmacological class, a principle well-established for opioids and benzodiazepines (Rao & Kumar, 2008; Landry et al., 1992). For GHB withdrawal, which can resemble severe alcohol or benzodiazepine withdrawal, high-dose benzodiazepines are used to manage symptoms like anxiety, tremor, and seizures by substituting for GHB's effects on the GABA system (Galloway et al., 1997; Moitroux & Kestens, 2023).

**Relapse Prevention and Long-Term Management**

The ultimate goal of treatment is to prevent relapse, which is driven by craving, conditioned cues, and stress (Stewart, 2003; Koob, 2020). Pharmacological strategies for relapse prevention aim to modulate the neurobiological systems that have become dysregulated through chronic drug use.

*   **Modulating Reward and Craving:** Although no specific anti-craving medications are approved for hallucinogen use disorder, this is a major area of research in the broader addictions field. The principle involves either blocking the rewarding effects of the drug (e.g., naltrexone for opioids and alcohol) or stabilizing the dysregulated neurochemical systems to reduce the motivation to use (Law & Nutt, 2012; Rao & Kumar, 2008). For example, some research is exploring agents that modulate the glutamate system to reduce cue-induced craving (Quintero Garzola, 2013).
*   **Treating Comorbid Psychiatric Disorders:** There is a high rate of comorbidity between SUDs and other psychiatric disorders like depression, anxiety, and psychosis (Buckley, 2007; Weaver et al., 2024). Treating these co-occurring conditions is critical, as they can be potent drivers of relapse (Nunes et al., 1995; McIntosh & Ritson, 2001). Antidepressants, particularly SSRIs, may be used to treat comorbid depression and anxiety, which may reduce the "self-medication" drive to use substances (Khantzian, 1990; Nunes et al., 1995). The biological mechanism involves correcting underlying serotonergic dysregulation, which may be a shared vulnerability factor for both depression and addiction (Malka, 1988).
*   **Paradoxical Therapeutic Potential:** An emerging and paradoxical area of research is the use of classic hallucinogens themselves, such as psilocybin and LSD, in controlled psychotherapeutic settings to treat addiction and other mental disorders (López‐Arnau et al., 2022; Cheung et al., 2023). The proposed mechanism is that these substances can induce profound psychological experiences that may enhance motivation for change, disrupt rigid patterns of thought and behavior, and promote neuroplasticity (López‐Arnau et al., 2022). This represents a shift from viewing these substances solely as drugs of abuse to potential therapeutic tools, although this research is still in early stages and requires rigorous investigation (Cheung et al., 2023).

### Future Directions

While our understanding of the biological underpinnings of Other Hallucinogen Use Disorder has advanced, it is clear that significant gaps in knowledge remain. The research available within this collection of literature highlights several critical areas that warrant further investigation to improve prevention, diagnosis, and treatment.

First, there is a pressing need for more research specifically focused on the neurobiology of hallucinogens, as distinct from other classes of abused substances like opioids or primary stimulants (Pechnick et al., 2014). Much of the current understanding of addiction neurobiology is based on a "common pathway" model centered on the mesolimbic dopamine system (Ivlieva, 2011). While this is a crucial component, the unique and profound perceptual and cognitive effects of serotonergic and dissociative hallucinogens suggest that they engage additional, distinct neural circuits. Future research should employ advanced neuroimaging and molecular techniques to delineate the specific, long-term effects of drugs like LSD, psilocybin, and ketamine on brain structure, function, and connectivity.

Second, the long-term consequences of hallucinogen use, particularly when initiated during the vulnerable period of adolescence, require more extensive longitudinal study (Hyytiä, 2015). Cross-sectional studies provide valuable snapshots, but only prospective, long-term research can definitively track the trajectory of brain development in young users and disentangle the causal relationships between substance use, cognitive deficits, and the emergence of other psychiatric disorders (Karila et al., 2014; Ornoy, 2002). Understanding whether drug-induced brain changes are reversible with abstinence is a key unanswered question with profound clinical implications (Hyytiä, 2015).

Third, the development of targeted pharmacotherapies for Other Hallucinogen Use Disorder remains a major challenge and a critical goal (Rastegar, 2020). The current therapeutic armamentarium is largely limited to managing acute intoxication or withdrawal and treating comorbid psychiatric conditions (Benyamina et al., 2003). There are no approved medications to specifically reduce craving or prevent relapse for hallucinogen dependence. Future research should focus on identifying and validating novel molecular targets within the serotonin, glutamate, and other relevant systems that could be modulated to restore the neurobiological homeostasis disrupted by chronic hallucinogen use (López‐Arnau et al., 2022).

Fourth, the paradoxical therapeutic potential of psychedelic hallucinogens represents a fascinating and rapidly evolving field of inquiry (Cheung et al., 2023; López‐Arnau et al., 2022). Rigorous, placebo-controlled clinical trials are needed to establish the efficacy and safety of psychedelic-assisted psychotherapy for a range of conditions, including SUDs, depression, and post-traumatic stress disorder (Cheung et al., 2023). Elucidating the neurobiological mechanisms of these therapeutic effects—whether through promoting neuroplasticity, altering functional connectivity in key brain networks, or modulating inflammatory pathways—could revolutionize psychiatric treatment (López‐Arnau et al., 2022).

Finally, the heterogeneity of Other Hallucinogen Use Disorder must be addressed. Individuals differ in their genetic vulnerability, psychological makeup, history of trauma, and pattern of substance use (Winters & Ingwalson, 2022; Johnson & Buisman‐Pijlman, 2016). Future research should aim to identify reliable biomarkers—whether genetic, neuroimaging, or neurochemical—that can help to stratify patients, predict treatment response, and personalize therapeutic interventions. A "one-size-fits-all" approach is unlikely to be successful for this complex and varied disorder.

### Conclusion

Other Hallucinogen Use Disorder is a clinically significant condition rooted in complex disruptions of the brain's fundamental biological systems. The progression from initial, often recreational, use to a state of compulsive drug-seeking and consumption is driven by potent drug-induced neuroadaptations within critical neural circuits governing reward, motivation, memory, and executive function (Koob, 2020; Ivlieva, 2011). The diverse pharmacological actions of hallucinogens—targeting serotonin, dopamine, and glutamate systems—produce a wide spectrum of acute psychological effects and contribute to distinct pathways of neuroplasticity that underpin the addictive process (Pechnick et al., 2014; Rastegar, 2020).

A key theme emerging from the literature is the concept of addiction as a disease of aberrant learning and memory, where drugs of abuse hijack the brain's natural reward-processing mechanisms (Müller, 2013; Scuvée‐Moreau, 2013). This leads to an overvaluation of drug-related cues and a diminished response to natural rewards, coupled with an impairment of prefrontal cortical control that results in a loss of control over drug use (Vanderschuren, 2008). The developing adolescent brain, with its immature executive control circuits and hypersensitive reward systems, is particularly vulnerable to these long-term disruptions (Hyytiä, 2015; Winters & Ingwalson, 2022).

Genetic predispositions and a history of early life stress or trauma further amplify this vulnerability, shaping an individual's susceptibility to developing a substance use disorder following drug exposure (Johnson & Buisman‐Pijlman, 2016; Ferrara, 2014). While our biological understanding has advanced, treatment options remain limited. Current pharmacological strategies are largely supportive, focusing on the management of acute intoxication, psychosis, and withdrawal, or the treatment of comorbid psychiatric conditions (Benyamina et al., 2003; Nunes et al., 1995).

The path forward requires a concerted research effort to unravel the specific neurobiological signatures of different classes of hallucinogens, to conduct longitudinal studies clarifying their long-term impact on the developing brain, and to identify novel molecular targets for the development of effective, evidence-based pharmacotherapies. The burgeoning exploration of the therapeutic potential of these same substances in controlled settings offers a paradoxical but promising new frontier (López‐Arnau et al., 2022). Ultimately, a deeper integration of neurobiological knowledge into clinical practice is essential to alleviate the significant personal and societal burden of Other Hallucinogen Use Disorder.

## References

1. Abascal, R. R., Sendin, P. M., & Juan, M. E. A. (2008). Adicciones en Anestesiología. Revista de la Escuela de Medicina Legal. https://doi.org/10.5209/rev_reml.2008.n9.50286
2. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
3. Adam, B. W., Lunow, M., & Seidel, G. (2010). Pseudo-Conn-Syndrom mit hypokaliämischer Lähmung bei Lakritzabusus und Diuretikatherapie. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0029-1245912
4. Albuquerque, A. C. D., Silva, J. R. D., & Silva, J. (2015). The “roundabout Man” Trapped in the “roundabout City” – a Case Report of a Severe Obsessive Compulsive Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)32056-3
5. Alldredge, B. K., & Simon, R. P. (2020). Drugs That Can Precipitate Seizures. CRC Press eBooks. https://doi.org/10.1201/9781003066736-69
6. Allen, P., Setya, A., & Lawrence, V. N. (2019). Pediatric Functional Constipation.
7. Alloy, L. B., & Abramson, L. Y. (2010). Cyclothymic Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0249
8. Alvarenga, E. C., Oliveira, P. D. T. R. D., Souza, L. C. D., & Barroso, R. F. F. (2016). Como é o atendimento em Saúde Mental feito pelas Equipes de Saúde da Família do Pará. 12º Congresso Internacional da Rede Unida.
9. Alzahrani, H., Alharazi, M., Alzahran, G., Alroudan, D., Marwi, A., AlJamea, J., Alsubie, M., Alqahtan, A., Alzaher, M., & Alahmadi, N. (2022). Relationship of Substance Abuse and Living Situation on Burn Survivors. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21208
10. Aman, M. G. (1990). Considerations in the use of psychotropic drugs in elderly mentally retarded persons. Journal of Intellectual Disability Research. https://doi.org/10.1111/j.1365-2788.1990.tb01510.x
11. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
12. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
13. Amron, S. B., Kandasami, G., Lee, C., Guo, S. L., & Tan, H. (2025). Making sense of ICD-11 diagnostic criteria of compulsive sexual behavioural disorder. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024266
14. Anis, A., Noor, S., & Shakeel, A. (2025). Attention deficit hyperactivity disorder: a misdiagnosed disorder. International Journal of Scientific Reports. https://doi.org/10.18203/issn.2454-2156.intjscirep20250752
15. Anisman, H., & Merali, Z. (1999). Understanding stress: characteristics and caveats.. PubMed.
16. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
17. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
18. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 2). Current psychiatry. https://doi.org/10.12788/cp.0253
19. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
20. Armstrong, E. (1995). Anxiety and related problems. https://doi.org/10.1007/978-1-349-13362-8_5
21. Arnone, J. M., & Conti, R. P. (2016). Kleine-Levin Syndrome: An Overview and Relevance to Nursing Practice. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20160219-07
22. Arnáez, S. (2019). Vulnerabilidad cognitiva a la hipocondría: intrusiones, valoraciones y creencias disfuncionales/ cognitive vulnerability to hypochondriasis: intrusions, appraisals and dysfunctional beliefs.
23. Arora, A., O'Neill, A., Crome, P., & Martin, F. C. (2014). Clinical Medicine and Substance Misuse. https://doi.org/10.1002/9781118430965.ch5
24. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
25. ARYANI, L. N. A., & MANIK, I. G. N. W. (2024). KOMORBIDITAS TRAUMA FISIK OKULI SINISTRA DAN GANGGUAN MENTAL PERILAKU AKIBAT ZAT MULTIPEL YANG MERUGIKAN PADA WARGA BINAAN LAPAS. HEALTHY Jurnal Inovasi Riset Ilmu Kesehatan. https://doi.org/10.51878/healthy.v3i1.2996
26. Ashok, K. (2017). Critical Review of Alcohol, Alcoholism and the Withdrawal Symptoms I. Mechanisms of Addiction and Withdrawal Syndrome. Archives of Addiction and Rehabilitation. https://doi.org/10.36959/843/421
27. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
28. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
29. Ayd, F. J. (1990). The Future of Anxiolytic Drug Therapy. International Review of Psychiatry. https://doi.org/10.3109/09540269009026608
30. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
31. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
32. Backer, W. D. (2006). Obstructive Sleep Apnea-Hypopnea Syndrome. KARGER eBooks. https://doi.org/10.1159/000093150
33. Baldaçara, L., Ramos, A., & Castaldelli-Maia, J. M. (2023). Managing drug-induced psychosis. International Review of Psychiatry. https://doi.org/10.1080/09540261.2023.2261544
34. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
35. Balhara, Y. S., Verma, R., & Mathur, S. (2011). Management of attention-deficit hyperactivity disorder. Journal of Pediatric Neurosciences. https://doi.org/10.4103/1817-1745.84400
36. Bansal, A., Saini, B., Rai, H., Dhillon, J. S., Bansal, P., & Saini, S. (2025). Dependence on ultra-high doses of gabapentinoids: A case series. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry_297_25
37. Baralatei, F. T., & Ackermann, R. J. (2016). Care of Patients at the End of Life: Management of Nonpain Symptoms.. PubMed.
38. Barch, D. M., Pagliaccio, D., Luking, K. R., Moran, E. K., & Culbreth, A. J. (2019). Pathways to Motivational Impairments in Psychopathology: Common Versus Unique Elements Across Domains. Nebraska Symposium on Motivation/The Nebraska symposium on motivation. https://doi.org/10.1007/978-3-030-27473-3_5
39. Bari, A., Robbins, T. W., & Dalley, J. W. (2010). Impulsivity. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_14
40. Barnhill, J. W., Okuda, M., Simpson, H. B., Stein, D. J., Simpson, H. B., Phillips, K. A., Phillips, K. A., Mataix‐Cols, D., Cruz, L. F. D. L., & Stein, D. J. (2023). Obsessive-Compulsive and Related Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615375295.jb06
41. Bartova, L., Dold, M., Volz, H. P., Seifritz, E., Möller, H., & Kasper, S. (2025). ANTIDEPRESSANT EFFECTS OF SILEXAN IN PATIENTS WITH PRIMARY ANXIETY SYNDROMES. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.065
42. Batista, M. E. D. S., Deuner, M. C., Nascimento, G. P. V. D., Silva, L. A. D. S., & Oliveira, G. O. B. D. (2025). BENZODIAZEPINES: IMMEDIATE BENEFITS, LONG TERM RISKS. https://doi.org/10.63330/aurumpub.009-003
43. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
44. Baumeister, R. F., Vonasch, A., & Sjåstad, H. (2020). The Long Reach of Self-Control. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780197500941.003.0002
45. Baving, L., & Olbrich, H. M. (1996). Alcoholism and Depression. European Addiction Research. https://doi.org/10.1159/000259099
46. Becker, H. C. (1998). Kindling in alcohol withdrawal.. PubMed.
47. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
48. Beebe, D. K., & Walley, E. (1991). Substance abuse: the designer drugs.. PubMed.
49. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
50. Benyamina, A., Bouchez, J., Rahioui, H., & Reynaud, M. (2003). [Psychiatric emergencies in drug addiction].. PubMed.
51. Bergman, B., & Brismar, B. (1998). The Significance of Alcohol for Violence and Accidents. Alcoholism Clinical and Experimental Research. https://doi.org/10.1097/00000374-199807001-00004
52. Bergman, B., & Brismar, B. (1998). The Significance of Alcohol for Violence and Accidents. Alcoholism Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.1998.tb04382.x
53. Bernetti, L., Corbelli, I., Romoli, M., Bedetti, C., Brahimi, E., Sarchielli, P., & Calabresi, P. (2015). P066. Migraine with aura in the locker room: 4 case reports. The Journal of Headache and Pain. https://doi.org/10.1186/1129-2377-16-s1-a169
54. Bersselaar, L. R. V. D., Hoeven, J. G. V. D., & Jong, B. D. (2020). Feeling Death, Being Alive: 4-Methylethcathinone/Pentedrone Addiction and 3-Methoxyphencyclidine Intoxication. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000214
55. Bismuth, C., Bellec, L., Dally, S., & Lagier, G. (1980). [Benzodiazepine physical dependence. 6 cases (author's transl)].. PubMed.
56. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
57. Bittencourt, L., Silva, R. S., Santos, R. F., Pires, M. L. N., & Mello, M. T. D. (2005). Sonolência excessiva. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462005000500004
58. Bixquert, M. (2013). Treatment of irritable bowel syndrome with probiotics: growing evidence.. PubMed.
59. Black, D. W. (1982). Pathological Laughter. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-198202000-00001
60. Blanco, S., Mitra, S., Howard, C. J., & Sumich, A. (2022). Psychological trauma, mood and social isolation do not explain elevated dissociation in functional neurological disorder (FND). Personality and Individual Differences. https://doi.org/10.1016/j.paid.2022.111952
61. Blunden, S., Etherton, H., & Hauck, Y. (2016). Resistance to Cry Intensive Sleep Intervention in Young Children: Are We Ignoring Children’s Cries or Parental Concerns?. Children. https://doi.org/10.3390/children3020008
62. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
63. Bolton, D., Hailu, T., & Porucznik, C. A. (2023). Resolution of stuttering during ketamine treatment: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-023-04158-8
64. Bordini, L., Riboldi, L., & Ferrario, M. (2013). [Psychotropic substances and driving].. PubMed.
65. Boren, R. A., & Boren, C. B. (2019). Charles Bonnet Syndrome Treated With Pimavanserin. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0000000000000800
66. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
67. Bosch, W. V. D., & Weel‐Baumgarten, E. V. (2003). [Depression: longer-lasting episode not an automatic indication for referral].. PubMed.
68. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
69. Boutros, N. N., & Bowers, M. B. (1996). Chronic substance-induced psychotic disorders: state of the literature. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.8.3.262
70. Bouwens, C., & Heyns, C. (2007). Assessment and management of urinary incontinence : main article. CME: Your SA Journal of CPD.
71. Boyer, S. (2016). Contribution de l'analyse du signal vocal à la détection de l'état de somnolence et du niveau de charge mentale.
72. Boyle, J., Danjou, P., Alexander, R., Calder, N., Gargano, C., Agrawal, N., Fu, I., McCrea, J. B., & Murphy, M. G. (2008). Tolerability, pharmacokinetics and night‐time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03331.x
73. Br, B., Roos, D., Beaufort, A. J. D., & Of, B. (1999). [The stumbling toddler].. PubMed.
74. Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. (2015). “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0731-4
75. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
76. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
77. Bronner, G., & Vodušek, D. B. (2011). Management of sexual dysfunction in Parkinson’s disease. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285611411504
78. Browne, R. B. (2011). The Belle Browne Pain Scale.
79. Bruch, S. (2013). Cultural concerns and issues in emergency psychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.041
80. Bruin, E. I. D., Meppelink, R., & Bögels, S. M. (2020). Mindfulness in attention deficit hyperactivity disorder. Routledge eBooks. https://doi.org/10.4324/9781315563862-7
81. Brüne, M., & Kahlert, I. (2001). Über einen Fall von primärer Zopiclonabhängigkeit. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-2001-14488
82. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
83. Buckley, P. (1999). The role of typical and atypical antipsychotic medications in the management of agitation and aggression.. PubMed.
84. Buckley, P. (2007). Dual Diagnosis of Substance Abuse and Severe Mental Illness: The Scope of the Problem. Journal of Dual Diagnosis. https://doi.org/10.1300/j374v03n02_07
85. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
86. Bujosa, C. M., & Monsalve, M. H. (2007). Caso Clínico "La esquizofrenia de inicio senil o cuando el reto de saber pseudodiagnosticar". Norte de Salud mental.
87. Buoli, M., Serati, M., & Cahn, W. (2015). Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2016.1135735
88. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
89. Burn, D. J. (2013). Approach to History Taking and Examination of the Movement Disorder Patient. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199609536.003.0002
90. Busto, E. D., Stoddard, F. R., & Cruz, J. S. (2016). Sexual Behaviors in Sleep. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780190245863.003.0003
91. Byard, R. W., & Tsokos, M. (2007). Forensic Issues in Cases of Diogenes Syndrome. American Journal of Forensic Medicine & Pathology. https://doi.org/10.1097/paf.0b013e31805f67e5
92. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
93. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Post-Stroke Apathy: An Exploratory Longitudinal Study. Cerebrovascular Diseases. https://doi.org/10.1159/000350202
94. Campagne, D. M. (2005). Venlafaxine and serious withdrawal symptoms: warning to drivers.. PubMed.
95. Cao, F., Salem, H., Nagpal, C., & Teixeira, A. L. (2017). Prolonged delirium misdiagnosed as a mood disorder. Dementia & Neuropsychologia. https://doi.org/10.1590/1980-57642016dn11-020014
96. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
97. Capece, J., & Pavlovsky, F. (2016). [The treatment of cannabis dependence: Clinical work, psychotherapy and evidence].. PubMed.
98. Caretta, F., & Petrini, M. (2006). La contenzione in ambito geriatrico. RIVISTA SPERIMENTALE DI FRENIATRIA. https://doi.org/10.1400/67163
99. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
100. Cash, E., Beck, I. T., & Davis, C. J. (2023). What factors influence individual differences in vulnerability/resilience to sleep loss and/or circadian misalignment?. Research Directions Sleep Psychology. https://doi.org/10.1017/slp.2023.6
101. Catheline, N. (2005). [Academic problems and school failure in adolescence].. PubMed.
102. Chaby, L., Cavigelli, S. A., White, A. M., Wang, K., & Braithwaite, V. A. (2013). Long-term changes in cognitive bias and coping response as a result of chronic unpredictable stress during adolescence. Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2013.00328
103. Chakraborty, K., & Bhide, A. (2020). General Principles for Psychotherapeutic Interventions in Children and Adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_811_19
104. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
105. Chandler, C. (2010). Glossary. https://doi.org/10.1002/9781444328172.gloss
106. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
107. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
108. Charlesworth, J., Ghosn, O., Hussain, N., Mahmoud, R., Goncalves, V., & Godbole, M. (2023). A case report of an unusual presentation of a patient with recurrent idiopathic catatonia. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100111
109. Charlton, S. R. (2020). Psychology and Black History Month in the United States. Eye on Psi Chi Magazine. https://doi.org/10.24839/2164-9812.eye24.4.18
110. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
111. Chavan, R., Gosavi, M., Baviskar, M., & Goyal, N. P. (2023). Depression Detection using AI, ML and NLP. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-8886
112. Chen, H., Albertson, T. E., & Olson, K. R. (2015). Treatment of drug‐induced seizures. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12720
113. Chernysheva, I. V., & Borodin, D. D. (2013). [Depressive state of rats in conditions of chronic combined stress caused by the combination of differently modal stressors].. PubMed.
114. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
115. Chicoș, O., Perri, D., Capriș, L., Iliescu, A. I. B., & Kantor, C. (2019). Social-Cultural Influences and Personality Disorders Favoring Drug Consumption. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s1/3
116. Chitsaz, A. (2017). Stroke And Substance Abuse. Advances in Bioscience and Clinical Medicine. https://doi.org/10.7575/aiac.abcmed.ca1.34
117. Chowdhry, S., & Kumar, N. (2022). Free Papers Compiled. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.341763
118. Chuen, L. H. (2022). Traditional Chinese Medicine Offers Help to Marijuana Users Determined to Withdraw Report of Two Typical Cases. Journal of Drugs Addiction & Therapeutics. https://doi.org/10.47363/jdat/2022(3)121
119. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
120. Cisneros, V., & Wray, A. (2017). Febrile Seizure. Journal of Education and Teaching in Emergency Medicine. https://doi.org/10.5070/m521033761
121. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
122. Coelho, C. M. M., Santos, G. X. C., Magano, S., Mota, D., Ferreira, S., Araújo, A. I., Cabaços, C., & Macedo, A. (2019). Treatment of Depersonalization-derealization Disorder With Transcranial Magnetic Stimulation. https://doi.org/10.26226/morressier.5d1a037457558b317a1404e8
123. Cohen, B. M. (1988). Persistence of Haloperidol in the Brain. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800330113019
124. Cohen, R., Pereira, I., Garrido, M. M., Ferreira, B., & Sousa, M. D. C. (2023). Suicidal ideation in older people, a public health matter. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1786
125. Cohn, L. M., & Caliendo, G. C. (1997). Guanfacine use in children with attention deficit hyperactivity disorder.. PubMed.
126. Colado, M. I., O’Shea, E., & Green, A. R. (2007). MDMA and Other “Club Drugs”. https://doi.org/10.1002/9780470101001.hcn039
127. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
128. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
129. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
130. Compton, M. T., & Broussard, B. (2010). Psychosocial Treatments for Early Psychosis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195372496.003.0016
131. Conaglen, H. M., & Conaglen, J. V. (2013). Drug-induced sexual dysfunction in men and women. Australian Prescriber. https://doi.org/10.18773/austprescr.2013.021
132. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
133. Cooper, L., Copeland, S., Dailey, S., Downey, D., Petersen, M. C., Stimson, C., & Dyke, D. C. V. (2008). Feeding and swallowing dysfunction in genetic syndromes. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.19
134. Corona, G., Mannucci, E., Petrone, L., Fisher, A. D., Balercia, G., Scisciolo, G. D., Pizzocaro, A., Giommi, R., Chiarini, V., Forti, G., & Maggi, M. (2006). Psychobiological Correlates of Delayed Ejaculation in Male Patients With Sexual Dysfunctions. Andrology. https://doi.org/10.2164/jandrol.05154
135. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
136. Corrêa, C. R. G. L. (2013). Attention – Deficit Hyperactivity Disorder (ADHD) in Psychiatry and Psychoanalysis. InTech eBooks. https://doi.org/10.5772/52880
137. Cortez-Vergara, C., Núñez-Moscoso, P., & Cruzado, L. (2013). Abuso de anticolinérgicos en pacientes con esquizofrenia: reportes de caso y breve revisión de la literatura.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v75i4.1218
138. Costa, G., Accattoli, M. P., Garbarino, S., Magnavita, N., & Roscelli, F. (2013). [Sleep disorders and work: guidelines for health surveillance, risk management and prevention].. PubMed.
139. Cox, R. C., Wright, K. P., Axelsson, J., & Balter, L. J. T. (2024). Diurnal variation in anxiety and activity is influenced by chronotype and probable anxiety-related disorder status. Psychiatry Research. https://doi.org/10.1016/j.psychres.2024.116006
140. Crippa, M., Toffoletto, F., & Torri, D. (2007). [Interactions between alcohol and work exposure to chemical substances].. La Medicina del lavoro.
141. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
142. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
143. Cüreoǧlu, S., FUKUSHIMA, H., Schachern, P. A., Paparella, M. M., & HARADA, T. (2005). The Effects of Type 2 Diabetes Mellitus on the Cochlear Structure in Human Temporal Bones. Otolaryngology. https://doi.org/10.1016/j.otohns.2005.05.545
144. Dagli, R. (2020). Fear and anxiety-coping strategies during COVID-19 pandemic in lockdown. Journal of international oral health. https://doi.org/10.4103/jioh.jioh_133_20
145. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
146. Daley, D. C., & Douaihy, A. (2019). Effects of Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0004
147. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
148. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
149. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
150. Damodaran, L., Singham, B., & Geyzel, L. V. (2019). G481(P) Prolonged sedation of an adolescent with intellectual disability: a multidisciplinary journey. https://doi.org/10.1136/archdischild-2019-rcpch.465
151. David, M., Lincoln, I., Anne, W., & Mutiso, V. (2011). Epidemiological Patterns of Anxiety Disorders in Kenya. InTech eBooks. https://doi.org/10.5772/19184
152. Davidson, M., Rashidi, N., Hossain, M. K., Raza, A., Nurgali, K., & Apostolopoulos, V. (2023). Tryptophan and Substance Abuse: Mechanisms and Impact. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032737
153. Davis, K. M., Chu, L. E., & Murdock, K. W. (2023). Burnout. CRC Press eBooks. https://doi.org/10.1201/b22810-10
154. Deelen, R. V., Rommers, M., Eerenberg, J., & Egberts, T. C. G. (2002). [Hypersexuality during use of levodopa].. PubMed.
155. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
156. Demaret, I., Lemaître, A., & Ansseau, M. (2013). [Heroin].. PubMed.
157. Denbeaux, M., Camoni, S. A., Beroth, B., Chrisner, M., Loyer, C., & Taylor, P. W. (2012). Drug Abuse: An Exploration of the Government's Use of Mefloquine at Guantánamo. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2002902
158. Dervaux, A. (2013). En quoi et comment le cannabis peut-il être toxique pour le cerveau ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.004
159. Dewailly, D., & Néraud, B. (2007). Drug-Induced Hyperandrogenism. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-179-6_10
160. Dhillon, R. S. (2013). The Potential for Abuse: Addiction. Berkeley Scientific Journal. https://doi.org/10.5070/bs3181020649
161. DiFazio, M., Silverberg, N. D., Kirkwood, M. W., Bernier, R., & Iverson, G. L. (2015). Prolonged Activity Restriction After Concussion. Clinical Pediatrics. https://doi.org/10.1177/0009922815589914
162. DiMartini, A. (2007). Natural history of alcohol use disorders in liver transplant patients. Liver Transplantation. https://doi.org/10.1002/lt.21342
163. Diwan, P. V., & Dikshith, T. S. S. (2003). Nonmedical Use of Drugs. https://doi.org/10.1002/0471426075.ch14
164. Djamshidian, A., Pagnier, G., Frank, M. J., & Friedman, J. H. (2022). Impulse Control Disorders and the Dopamine Dysregulation Syndrome. Cambridge University Press eBooks. https://doi.org/10.1017/9781009039291.021
165. Dobrescu, I., Rad, F., Anghel, G. C., Stancu, M., & Buică, A. (2017). P288 Somatic complaints in anxiety disorders. https://doi.org/10.1136/archdischild-2017-313273.376
166. Dobry, Y., Braquehais, M. D., & Sher, L. (2013). Bullying, psychiatric pathology and suicidal behavior. International Journal of Adolescent Medicine and Health. https://doi.org/10.1515/ijamh-2013-0065
167. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
168. Dodge, N. C., Jacobson, J. L., Lundahl, L. H., & Jacobson, S. W. (2023). Prenatal alcohol exposure and attention‐deficit/hyperactivity disorder independently predict greater substance use in young adulthood. Alcohol Clinical and Experimental Research. https://doi.org/10.1111/acer.15076
169. Dorard, G., & Benarbia, A. (2017). Chemsex : definition and healthcare access matter. European Health Psychologist.
170. Dore, G., & Sweeting, M. (2006). Drug-Induced Psychosis Associated with Crystalline Methamphetamine. Australasian Psychiatry. https://doi.org/10.1080/j.1440-1665.2006.02252.x
171. Dore, G., & Sweeting, M. (2006). Drug-induced psychosis associated with crystalline methamphetamine. Australasian Psychiatry. https://doi.org/10.1111/j.1440-1665.2006.02252.x
172. Dorresteijn, S. M., Ploeg, E. V. D., & Kleber, R. J. (2003). Critical incidents and chronic stressors at work: Their impact on forensic doctors.. Journal of Occupational Health Psychology. https://doi.org/10.1037/1076-8998.8.2.157
173. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
174. Dubicka, B., & Wilkinson, P. (2007). Evidence-based treatment of adolescent major depression. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.10.4.100
175. Duffard, A. M. E. D., & Duffard, R. (1996). Behavioral toxicology, risk assessment, and chlorinated hydrocarbons.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.96104s2353
176. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
177. Dunnigan, M., Czapla, K., Henderson, J. B., & Pelosi, A. J. (1999). The Fluid Retention Syndrome: Recognition, Risk Factors and Management. The Journal of the British Menopause Society. https://doi.org/10.1177/136218079900500206
178. Dydak, K., Śliwińska‐Mossoń, M., & Milnerowicz, H. (2015). [Psilocybin - public available psychodysleptic].. PubMed.
179. Dåderman, A. M., & Lidberg, L. (1999). [Rohypnol should be classified as a narcotic].. PubMed.
180. Ebenezer, I. S. (2015). Affective Disorders 2: Bipolar Disorder. https://doi.org/10.1002/9781118385777.ch7
181. Ebenezer, I. S. (2015). Drug Abuse and Addiction. https://doi.org/10.1002/9781118385777.ch11
182. Eckert, W. G. (1982). Physician crimes and criminals. American Journal of Forensic Medicine & Pathology. https://doi.org/10.1097/00000433-198209000-00007
183. Ecoffey, B. (2002). Recovery and outcome after minor pediatric surgery.. PubMed.
184. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
185. Eichner, E. R. (1995). Overtraining: Consequences and prevention. Journal of Sports Sciences. https://doi.org/10.1080/02640419508732276
186. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
187. Erstad, B. L., & Cotugno, C. L. (1995). Management of alcohol withdrawal. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/52.7.697
188. Escobedo, A. D. Á. (2012). Influencia del estrés y depresión prenatal en el desarrollo del niño. Revista Peruana de Pediatría. https://doi.org/10.61651/rped.2012v65n3p158-169
189. Espinoza, H., & Vicente, J. (2015). Trastorno por ansiedad en paciente de 46 años de escolarización medio con tratamiento psicoterapéutico en modelo psicológico cognitivo conductual..
190. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
191. Faeder, M., Hale, E., Hedayati, D., Israel, A., Moschenross, D., Peterson, M., Peterson, R., Piechowicz, M., Punzi, J., & Gopalan, P. (2023). Preventing and treating delirium in clinical settings for older adults. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231198462
192. Fasano, A., Elia, A. E., Soleti, F., Guidubaldi, A., & Bentivoglio, A. R. (2006). Punding and computer addiction in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.20787
193. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
194. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
195. Feldtmann, E., Pointdujour, P., Bellido, C., & Preuss, C. (2023). Diagnosis and Management of Social Anxiety Disorder. CRC Press eBooks. https://doi.org/10.1201/9781003333821-3
196. Ferrara, P. (2014). Child abuse and neglect: psychiatric and neuro-biological consequences. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a32
197. Flaer, P. J. (2015). Co-Morbidity of Obsessive-Compulsive Disorder (OCD) and Chronic Depression. Clinical and Experimental Medical Letters.
198. Flannery, H. S. S. M. J. K. C. L. J. K. L., & Newlin, D. B. (2008). Alcohol Use Disorders and Their Treatment. https://doi.org/10.1093/oso/9780195300550.003.0018
199. FM, P., & FP, J. (2015). Persistent Genital Arousal Disorder as a Dissociative Trauma Related Condition Treated with Brainspotting A Successful Case Report. International Journal of School and Cognitive Psychology. https://doi.org/10.4172/2469-9837.1000s1-002
200. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
201. Forray, A. (2016). Substance use during pregnancy. F1000Research. https://doi.org/10.12688/f1000research.7645.1
202. Fraga, J. A. G., & Conesa, P. M. (2006). Valoración del enfermo drogodependiente en los Servicios de Urgencias. Adicciones.
203. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
204. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
205. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
206. Fregonese, L., Silvestri, M., Sabatini, F., Defilippi, A., & Rossi, G. A. (2001). Severe and near-fatal asthma in children and adolescents.. PubMed.
207. Frock, B., Williams, A., & Caplan, J. P. (2016). Pseudobulbar Affect: When Patients Laugh or Cry, but Don't Know Why. Current psychiatry.
208. Frymark, T., Leech, H. M., Mullen, R., Schooling, T., Venediktov, R., & Wang, B. (2010). Evidence-Based Systematic Review (EBSR): Drug-Induced Hearing Loss— Aminoglycosides.
209. Fuente, J. R. D. L., & Kershenobich, D. (1992). I. El alcoholismo como problema médico. Revista de la Facultad de Medicina.
210. Gallino, G., & Liffredo, C. (1993). [Inappropriate drug use in elderly patients. Considerations on various psychologic aspects].. PubMed.
211. Galloway, G. P., Frederick, S., Staggers, F. E., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997). Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. https://doi.org/10.1046/j.1360-0443.1997.921899.x
212. Galloway, G. P., Frederick, S., Staggers, F. E., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997). Gamma‐hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. https://doi.org/10.1111/j.1360-0443.1997.tb03640.x
213. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
214. Garzola, G. C. Q. (2013). Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s45963
215. Garzoni, L., Vanoni, F., Rizzi, M., Simonetti, G. D., Simonetti, B. G., Ramelli, G. P., & Bianchetti, M. G. (2009). Nervous system dysfunction in Henoch-Schonlein syndrome: systematic review of the literature. Lara D. Veeken. https://doi.org/10.1093/rheumatology/kep282
216. Gaudiano, B. A. (2012). The Need to Develop Innovative Interventions to Improve Treatment Adherence in Co-Occurring Severe Mental Illness and Substance Use Disorders. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.s8-e001
217. Genazzani, A. D., Ricchieri, F., Lanzoni, C., Strucchi, C., & Jasonni, V. M. (2006). Diagnostic and Therapeutic Approach to Hypothalamic Amenorrhea. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1365.009
218. Ghasemian, D., D’Souza, L., & Ebrahimi, S. (2012). Effectiveness of Rational Emotive Behaviour Therapy on Shyness: Influence of Age. JOURNAL OF PSYCHOSOCIAL RESEARCH.
219. Giacomo, E. D., Alamia, A., Cicolari, F., Cimolai, V., & Clerici, M. (2014). [Sexual abuse in adulthood: when psychic and somatic suffering merge].. PubMed. https://doi.org/10.1708/1600.17454
220. Giacomo, E. D., Aspesi, F., & Clerici, M. (2013). 1756 – Child sexual abuse andnarcissism: a case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)76734-8
221. Giannopoulos, I., Jupe, T., & Provi, K. (2024). Sleep architecture disturbance due to the use of benzodiazepines. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1614
222. Giarenis, I., & Cardozo, L. (2013). Management of refractory overactive bladder.. PubMed.
223. Giménez, V. M. M., Mazzei, L., Sanz, R., & Manucha, W. (2022). Cannabinoids as Potential Molecules for Addiction Disorders. Current Protein and Peptide Science. https://doi.org/10.2174/1389203723666220510121031
224. Girolamo, G. D., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2011). Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796011000746
225. Givler, D., Givler, A., Luther, P. M., Wenger, D. M., Ahmadzadeh, S., Shekoohi, S., Edinoff, A. N., Dorius, B., Baptiste, C. J., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2023). Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurology International. https://doi.org/10.3390/neurolint15010031
226. Glasgow, H. B., Burkholder, J. M., Schmechel, D. E., Tester, P. A., & Rublee, P. A. (1995). Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. Journal of Toxicology and Environmental Health. https://doi.org/10.1080/15287399509532051
227. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking. JAMA. https://doi.org/10.1001/jama.264.12.1583
228. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking.. PubMed.
229. Gleason, M. M., & Thompson, L. A. (2022). Depression and Anxiety Disorder in Children and Adolescents. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2022.0052
230. Gold, B. G., Schnell, J. V., & Spencer, P. S. (2003). Neurotoxic Disorders. https://doi.org/10.1007/978-1-4757-4552-8_14
231. Gold, D. G., & Fatemi, S. H. (2003). Phenelzine–Opiate–Induced Delirium Complicated by Phenelzine Withdrawal. Journal of Pharmacy Technology. https://doi.org/10.1177/875512250301900106
232. Gomathy, S. B., Saini, A., Gupta, A., Vishnu, V. Y., Singh, M. B., Bhatia, R., Srivastava, M. P., Radhakrishnan, D. M., Srivastava, A. K., & Rajan, R. (2024). A rare yet treatable case of paroxysmal kinesigenic dyskinesia. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_28_23
233. Gorman, W. F. (1982). Defining malingering.. PubMed.
234. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
235. Gram, L. F., Brøsen, K., Sindrup, S. H., & Skjelbo, E. (1993). Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. Nordic Journal of Psychiatry. https://doi.org/10.3109/08039489309102787
236. Granger, C. E., & Shelly, M. P. (1996). Stressing out, or outing stress?. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199611000-00001
237. Grant, I., Sacktor, N., & McArthur, J. C. (2005). HIV neurocognitive disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0035
238. Graziani, P. (2011). La consommation excessive d’alcool chez la personne âgée. Drogues santé et société. https://doi.org/10.7202/1005300ar
239. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
240. Griffiths, M. D., Hodgson, R. J., & Budd, R. (2001). Compulsive Behaviours. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_131
241. Guerdjikova, A. I., & McElroy, S. L. (2015). Kleptomania. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp147
242. Guith, D. M. (1996). Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy. Journal of Pharmacy Practice. https://doi.org/10.1177/089719009600900208
243. Gupta, R., Singh, A. P., Mittal, A., & Chaturvedi, S. K. (2024). "FROM BOOST TO BREAKDOWN "PERFORMANCE ENHANCEMENT AND THE DARK SIDE OF MEPHENTERMINE ADDICTION” A CASE SERIES. Global Journal For Research Analysis. https://doi.org/10.36106/gjra/0506138
244. Guthrie, M., Zubatsky, M., & Smith, C. W. (2015). Family Stress and Counseling. Family Medicine. https://doi.org/10.1007/978-1-4939-0779-3_30-1
245. Gómez, M. V. (2005). Cefalea crónica diaria: II. Tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.4003.2004387
246. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
247. Güngörmüş, Z., & Özgüç, S. (2025). Psychosocial problems observed in older adults after disaster. Psychogeriatrics. https://doi.org/10.1111/psyg.70001
248. Hainline, B., Gurin, L., & Torres, D. M. (2019). Multiple Concussions and Retirement from Sport. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0028
249. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
250. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
251. Hechtman, L. (1991). Resilience and Vulnerability in Long Term Outcome of Attention Deficit Hyperactive Disorder. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674379103600606
252. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
253. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
254. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
255. Hoehn‐Saric, R., Lipsey, J. R., & McLeod, D. R. (1990). Apathy and Indifference in Patients on Fluvoxamine. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199010000-00007
256. Hoell, I., & Havemann‐Reinecke, U. (2011). [Pregnant opioid addicted patients and additional drug intake. Part I. Toxic effects and therapeutic consequences].. PubMed.
257. Hofland, S. L., & Dardis, P. O. (1992). BULIMIA NERVOSA: Associated Physical Problems. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/0279-3695-19920201-07
258. Holcát, M. (2007). [Tinnitus and diabetes].. PubMed.
259. Hollander, E., & Aronowitz, B. (1999). Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient.. PubMed.
260. Howland, R. H. (2014). Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20131217-01
261. Howland, R. H. (2014). Psychotropic Medication Use:What Will It Do To My Liver?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20140722-01
262. Huda, A. S. (2019). Social factors and health. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198807254.003.0013
263. Hurd, Y. L. (1996). Cocaine Effects on Dopamine and Opioid Peptide Neural Systems: Implications for Human Cocaine Abuse. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-006
264. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
265. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
266. Häussler, S. (1984). [Work incapacity within the scope of rehabilitation].. PubMed.
267. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
268. Imfeld, C., & Imfeld, T. (2005). [Eating disorders (I)--medical and psychiatric aspects].. PubMed.
269. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
270. Iqbal, S., & Srivatsav, C. B. P. (1984). Chloramphenicol ototoxicity. A case report.. PubMed.
271. Iqbal, S., & Srivatsav, C. B. P. (1984). Cholarmphenicol ototoxicity. The Journal of Laryngology & Otology. https://doi.org/10.1017/s0022215100147000
272. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
273. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
274. Jaffee, M. S., Broshek, D. K., & Svingos, A. M. (2023). Can Having Attention-Deficit/Hyperactivity Disorder or a Learning Disorder Complicate Recovery from Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190630119.003.0011
275. Jagtiani, A., Nagi, T., Gandhi, R., & Rizvi, A. (2024). Clozapine Withdrawal Catatonia: A Case Report. Cureus. https://doi.org/10.7759/cureus.52462
276. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
277. Jansen, K. (1990). Ketamine–Can Chronic Use Impair Memory. International Journal of the Addictions. https://doi.org/10.3109/10826089009056204
278. Jc, N., Nicholson, K. L., Bl, P.-J., & Undén, M. (1995). [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].. PubMed.
279. Jefferson, R. D., Bateman, D. N., Thomas, S. H., Thompson, J. P., & Vale, J. A. (2014). Drugs of abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199594740.003.0008
280. Jehanzeb, S., & Javaid, A. (2025). The Life-Changing Diagnosis in a Patient With Treatment-Resistant Depression, From Darkness to Light and Healing. BJPsych Open. https://doi.org/10.1192/bjo.2025.10735
281. Jing-y, L. (2013). Attentional defects induced by chronic drug abuse. Journal of Capital Medical University.
282. Johnson, J., & Buisman‐Pijlman, F. (2016). Adversity impacting on oxytocin and behaviour: timing matters. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000269
283. Johnston, M. P., & Coward, D. D. (2001). Cancer-Related Fatigue: Nursing Assessment and Management. AJN American Journal of Nursing. https://doi.org/10.1097/00000446-200104001-00005
284. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
285. Joseph, A. B., & Wroblewski, B. (1993). Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. Brain Injury. https://doi.org/10.3109/02699059309029690
286. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
287. Järvholm, S. (2022). [Psychological aspects of infertility].. PubMed.
288. Kacir, C. D. (2010). The Evolutionary Bases of Substance Use and Abuse. Forum on public policy.
289. Kaiser, N., & Hoza, B. (2007). Self-Esteem and Self-Perceptions in ADHD. CRC Press eBooks. https://doi.org/10.3109/9781420017144-7
290. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
291. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
292. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
293. Kancherla, N., Garlapati, S. K. P., Sowkhya, P., Yegateela, T., & McCrary, A. (2022). A Case of Coexisting Depression and Hoarding Disorder. Cureus. https://doi.org/10.7759/cureus.25645
294. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
295. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
296. Kaware, M. A. S., Dudhe, M. P. V., Chavhan, M. N. R., Naveria, M. A., & Rajeshwari, K. R. (2024). An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it’s Interaction with Other Drugs which are Already in use Respect to Other Disease. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-18578
297. Kerfoot, M. (2005). Partnerships between health and local authorities. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508441.003.0008
298. Khadka, S., Singh, P., Khadka, M., Chakrabarti, K., Pandit, S., Dhonju, G., & Gautam, S. (2019). A Case Report On Fluoro-Quinolones (Ofloxacin) Induced Psychosis At Nepal Medical College Teaching Hospital. Journal of Psychiatrists Association of Nepal. https://doi.org/10.3126/jpan.v8i2.28029
299. Khanna, R., White, L., Bessey, F. Y., Borntrager, E., Hoberg, A., & Caplan, J. P. (2022). Barriers to Treatment of Hallucinations and Delusions in People With Dementia Residing in Long-Term Care. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.21m14050
300. Khantzian, E. J. (1990). Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences.. PubMed.
301. Kiecolt‐Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015). Inflammation: Depression Fans the Flames and Feasts on the Heat. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15020152
302. Kim, B. (2019). Pharmacotherapy for attention-deficit/hyperactivity disorder. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2019.62.1.49
303. Kim, J., Mi-Kyung, L., Choi, S.-S., Eui-Seok, P., & Gwi-Eun, Y. (2015). Continuous Cervical Epidural Block for Persistent Intractable Hiccups.
304. Kintz, P., Villain, M., & Cirimele, V. (2008). Chemical Abuse in the Elderly: Evidence From Hair Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0b013e31816bac44
305. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
306. Kirkby, K. C. (2007). Recognising and Responding to Candidates' Health Needs. ACER Press eBooks.
307. Knapp, M. (2001). Economic Evaluation of Mental Health Care. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_16
308. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
309. Koob, G. F. (2014). PL1 * ADDICTION AS A REWARD, STRESS AND EXECUTIVE FUNCTION DISORDER. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu051.1
310. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
311. Kopa, Z., & Romics, I. (2011). Treating erectile dysfunction. Clinical and Experimental Medical Journal. https://doi.org/10.1556/cemed.5.2011.28800
312. Kopp, S., & Gillberg, C. (2022). [Symptoms, diagnostic process and outcome in girls and women with ADHD].. PubMed.
313. Kosten, T. R. (1991). Client issues in drug abuse treatment: addressing multiple drug abuse.. PubMed.
314. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
315. Kotowicz, K., Gawęda, Ł., Misiak, B., & Frydecka, D. (2020). The role of the cognitive biases along the psychosis continuum: from pathophysiology to treatment options. Archives of Psychiatry and Psychotherapy. https://doi.org/10.12740/app/130365
316. Kovalenko, A. L., Sinenchenko, A. G., & Lodyagin, A. N. (2022). [CLINICAL CASE OF ACUTE SEVERE COMBINED POISONING WITH NARCOTIC SUBSTANCES OF DEPENDENT AND PSYCHOSTIMULATING EFFECTS].. PubMed.
317. KOYNER, F. G., Barrera, N. P., Subedi, P., Shrestha, K., & Cerrud‐Rodriguez, R. (2024). When Two Syndromes Collide: Managing Fanconi and Refeeding Syndrome in a Single Patient. Cureus. https://doi.org/10.7759/cureus.52169
318. Krishnan, J. (2024). MDMA (3,4-methylenedioxy-methamphetamine). BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010004
319. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
320. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
321. Kumar, A., Prasad, S., Mallik, S., & Choudhary, R. J. (2025). Persistent Delusional Disorder Presenting as Munchausen by Proxy - A Case Report. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20250249
322. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
323. Kuzminov, V. (2019). he dependence of the clinical picture of acute psychosis connected with alcohol withdrawal from the forms of alcohol consumption. Ukrains kyi Visnyk Psykhonevrolohii. https://doi.org/10.36927/2079-0325-v27-is1-2019-16
324. Lader, M., & Morris, R. G. (2001). Carbon Monoxide Poisoning. Journal of the Royal Society of Medicine. https://doi.org/10.1177/014107680109401029
325. Landry, M. J., Smith, D. E., McDuff, D., & Baughman, O. L. (1992). Benzodiazepine dependence and withdrawal: identification and medical management.. PubMed.
326. Langguth, B., Bär, R., Wodarz, N., Wittmann, M., & Laufkötter, R. (2011). Paradoxical Reaction in ADHD. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0541a
327. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
328. Law, F., & Nutt, D. (2012). Drugs used in the treatment of the addictions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0158
329. Lee, M. A., McGlinch, E. B., McGlinch, M., & Capacchione, J. F. (2017). Malignant Hyperthermia Susceptibility and Fitness for Duty. Military Medicine. https://doi.org/10.7205/milmed-d-16-00186
330. Lee, Y. L. (2003). Central neurological abnormalities and multiple chemical sensitivity caused by chronic toluene exposure. Occupational Medicine. https://doi.org/10.1093/occmed/kqg095
331. Leiblum, S. R. (2003). Arousal disorders in women: complaints and complexities. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2003.tb05392.x
332. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
333. Lemcke, H.-J. (1996). DAS "HWS-SCHLEUDERTRAUMA" AUS JURISTISCHER SICHT. NZV - NEUE ZEITSCHRIFT FUER VERKEHRSRECHT.
334. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
335. Lerner, S. E., Burns, R. S., Corrado, R. R., James, S., & Schnoll, S. H. (1975). Phencyclidine--states of acute intoxication and fatalities.. PubMed.
336. Li, X., & Li, S. X. (2022). Paediatric Insomnia. https://doi.org/10.1007/978-981-19-5791-8_6
337. Li, Z., Goh, S. N., Teo, Y. W., & How, C. H. (2023). Management of intimate partner abuse. Singapore Medical Journal. https://doi.org/10.4103/singaporemedj.smj-2021-452
338. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
339. Lim, H., Kwon, Y.-J., Lee, J.-E., & Cho, S. (2013). Reconsideration of Psychasthenia- Two Cases. Journal of Oriental Neuropsychiatry. https://doi.org/10.7231/jon.2013.24.3.245
340. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
341. Lipsey, J. R. (2008). Electroconvulsive Therapy. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195309430.003.0029
342. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
343. Liu, T., Song, X.-M., Chen, G., & Zheng, X. (2013). [Violent behavior in people with schizophrenia: a review].. PubMed.
344. Lobato, E. F. (2013). Persistent hiccup treated by hypnosis. Revista Médica de Minas Gerais. https://doi.org/10.5935/2238-3182.20130040
345. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
346. Ludes, B. (2002). [Child abuse].. PubMed.
347. Lutz, E. G. (1976). Neuroleptic-lnduced Akathisia and Dystonia Triggered by Alcohol. JAMA. https://doi.org/10.1001/jama.1976.03270220042034
348. López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022). 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.990405
349. López‐Caneda, E., Holguı́n, S. R., Cadaveira, F., Corral, M., & Doallo, S. (2013). Impact of Alcohol Use on Inhibitory Control (and Vice Versa) During Adolescence and Young Adulthood: A Review. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agt168
350. Macho, L. P., & Andrés, S. B. (2010). Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009740
351. Madea, B., & Hagemeier, L. (2013). [Death by erotic asphyxiation (breath control play)].. PubMed.
352. Majewska, M. (1996). Cocaine Addiction as a Neurological Disorder: Implications for Treatment. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-002
353. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
354. Malka, R. (1988). Role of drug therapies in the treatment of alcoholism: alcohol and anxiety--alcohol and depression.. PubMed.
355. Malt, U. F., Lingjærde, O. C., Berg-Larsen, R., Bratholm, J., Lersbryggen, A. B., Notland, T. H., Olavesen, B., Oscarsson, K., Uren, G., & Vaagen, T. (1990). [Schizophrenic patients and the emotional climate in the family. Causes, consequences and treatment of intensely expressed emotions of close relatives].. PubMed.
356. Manuchehri, A. A., Alijanpour, E., Daghmechi, M., Ghaeminan, N., Abedi, S. H., Nikbakhsh, N., Saeed, S. A. M. G. M., & Amani, N. (2015). A case of methanol poisoning leading to prolonged respirator dependency with consequent blindness and irreversible brain damage.. PubMed.
357. Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023). Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients. https://doi.org/10.1007/978-3-031-30093-6_4
358. Markland, A. D., Busby‐Whitehead, J., & Whitehead, W. E. (2022). Fecal Incontinence. Cambridge University Press eBooks. https://doi.org/10.1017/9781108942751.029
359. Marshall, L. L., & Bailey, W. (2008). Urinary Incontinence Management in Geriatric Patients. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2008.681
360. Mary, L. A. (2013). A Study on Depression, Anxiety and Quality of Life ofChronic Renal Failure Patients on Maintenance Hemodialysis..
361. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
362. Masdrakis, V. G., Turic, D., & Baldwin, D. S. (2013). Pharmacological Treatment of Social Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351960
363. Mattison, A., & Cherner, M. (2005). Club drugs and HIV transmission. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0067
364. Mc, M.-S. (1993). [Post-traumatic stress syndrome in children].. PubMed.
365. McCaffrey, R. J., & Lynch, J. K. (2008). Malingering following documented brain injury: Neuropsychological evaluation of children in a forensic setting. Psychology Press eBooks. https://doi.org/10.4324/9780203890042-37
366. McEvoy, J. P., Asuzu, K., Bradford, D. W., Freudenreich, O., & Moyer, K. (2020). Treatment and management of patients with schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0065
367. McIntosh, C., & Ritson, B. (2001). Treating depression complicated by substance misuse. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.7.5.357
368. McLeod, T. C. V., & Register‐Mihalik, J. K. (2011). Clinical Outcomes Assessment for the Management of Sport-Related Concussion. Journal of Sport Rehabilitation. https://doi.org/10.1123/jsr.20.1.46
369. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
370. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
371. Meena, D., Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v7i6.592
372. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
373. Menezes, M. C. D. C., Gonçalves, L. G. V., Chaves, S. C. D. S., Jaime, T. F. M., Oliveira, I. C. Z., Sobrinho, K. D. L., Oliveira, L. L. D., Araújo, J. V. L. D., Gurian, F. G., Soares, I. L. T., Nero, L. D., Pereira, P. H. D. O., Moraes, F. D. C., & Teixeira, G. P. (2023). MAIN CAUSES OF INTENTIONAL ACCIDENTS IN PEDIATRICS AND CLINICAL MANIFESTATIONS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593712308095
374. Mengin, A. C., Allé, M. C., Rolling, J., Ligier, F., Schröder, C., Lalanne, L., Berna, F., Jardri, R., Vaïva, G., Geoffroy, P. A., Brunault, P., Thibaut, F., Chevance, A., & Giersch, A. (2020). [Psychopathological consequences of confinement]./ Conséquences psychopathologiques du confinement.. Encephale-revue De Psychiatrie Clinique Biologique Et Therapeutique.
375. Mercieri, M., Mercieri, A., & Pedrini, L. A. (2005). Baclofen neurotoxicity in chronic hemodialysis. Hemodialysis International. https://doi.org/10.1111/j.1492-7535.2005.1121bb.x
376. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
377. Michel, J., Gisselbaek, A., Gauthey, L., & Zelger, G. L. (1993). [Non-compliant drug taking in elderly subjects].. PubMed.
378. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
379. Miller, D. D. (2007). Sedation with Antipsychotics: Manage, Don't Accept Adverse 'Calming' Effect. Current psychiatry.
380. Mir, J. A., Mushtaq, B., Mushtaq, O. A., & Ali, F. S. (2022). Case report on schizophrenia: Application of paplaus model theory in nursing care plan. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.014
381. Mlakar, P., & Stare, J. (2014). Some Characteristics of Employees as Risk Factors for Presenteeism. Central European Public Administration Review. https://doi.org/10.17573/ipar.2013.2.a02
382. Modigh, K., Berggren, U., & Sehlin, S. (1998). [High risk for children with DAMP/ADHD to become addicts later in life].. PubMed.
383. Moguel, B., Armenta, M., & Hernández, V. (1993). [Clinico-pathologic correlation of dementia produced by thinner and cocaine].. PubMed.
384. Mohammadi, M. R., & Akhondzadeh, S. (2007). Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.2.195
385. Mohanty, I., Arunvikram, K., Sardar, K. K., Palai, S., Sahoo, G., & Patra, R. C. (2014). Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. https://doi.org/10.14202/vetworld.2014.299-305
386. Moitroux, A., & Kestens, C. (2023). [Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB)].. PubMed.
387. Molero‐Chamizo, A. (2005). 3,4-metilenodioximetanfetamina (‘éxtasis’): efectos emocionales y cognitivos a largo plazo y depleción serotoninérgica. Revista de Neurología. https://doi.org/10.33588/rn.4102.2004547
388. Molleman, P. W., Kesteren, J. V., Ubink-Bontekoe, C., Zoomer-Hendriks, M. P. D., & Wetzels, R. B. (2015). [Canopy-enclosed bed for dementia patients with behavioural problems].. PubMed.
389. Montoya-Cabrera, M. A. (1990). [Poisoning caused by neuroleptics and other related drugs].. PubMed.
390. Moore, B. A., Bowden‐Jones, H., Budney, A. J., & Vandrey, R. G. (2008). Treatment of cannabis dependence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544392.024
391. Moore, K. E., Stein, M. D., Kurth, M. E., Stevens, L., Hailemariam, M., Schonbrun, Y. C., & Johnson, J. E. (2019). Risk factors for self-stigma among incarcerated women with alcohol use disorder.. Stigma and Health. https://doi.org/10.1037/sah0000182
392. Mudgal, V., Mishra, S., Mathur, R., & Dua, S. (2025). The Sound of Obsession: An Unusual Case Report of Misophonia and Obsessive–Compulsive Disorder. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_158_23
393. Muliyala, K. P., Lima, C. A. D. M., & Chong, D. (2024). S9: Addictions in Later Life an Emerging Crisis. International Psychogeriatrics. https://doi.org/10.1017/s104161022400111x
394. Mushthi, D., Chakraborty, R., Chaudhury, S., & Singh, A. (2025). Olanzapine-induced akathisia treated with clozapine. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_268_24
395. Müller, C. P. (2013). Episodic Memories and Their Relevance for Psychoactive Drug Use and Addiction. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2013.00034
396. Müller, K., Gehl, A., Ottens, R., & Püschel, K. (2011). [Suicide by hypothermia with intentional partial undressing].. PubMed.
397. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
398. Nagireddy, R. B. R., & Joshi, D. (2020). Phenytoin induced chorea: an uncommon manifestation. Authorea (Authorea). https://doi.org/10.22541/au.159109589.94248103
399. Naidoo, S. (2015). Managing stress in the dental environment.
400. Nakamura, M., & Inoue, Y. (2013). [Characteristic and treatment of insomnia in dementia].. PubMed.
401. Nayak, R. D. (2015). Internet Addiction a Comparative Study between Undergraduate Students of India and Malaysia. International Journal of Indian Psychology. https://doi.org/10.25215/0204.088
402. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
403. Nielsen, J. F., Klemar, B., Hansen, H., & Sinkjær, T. (1995). A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254-a
404. Nijdam, S. J. (1990). [Anxiety and depression caused by side effects of drugs].. PubMed.
405. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
406. Norman, E. M., Ferner, R. E., & Rawlins, M. D. (1995). Effects of drugs on behaviour. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198548263.003.0005
407. Nosek, M. A., & Howland, C. A. (1998). Abuse and Women with Disabilities.
408. Ns, M., & Gold, M. S. (1990). The contemporary alcoholic.. PubMed.
409. Nubukpo, P., Laot, L., & Clément, J. (2012). Addictive behaviors in the aged. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2012.0355
410. Nunes, E. V., McGrath, P. J., & Quitkin, F. M. (1995). Treating anxiety in patients with alcoholism.. PubMed.
411. Nunes, J. T., Brigadeiro, D., Andrade, J., & Costa, A. P. D. (2017). Neuroleptic-induced Parkinsonism in Patient with Obsessive Compulsive Disorder: A Case Report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1063
412. Ogbonna, C. I., & Lembke, A. (2017). Tapering Patients Off of Benzodiazepines.. PubMed.
413. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
414. Olsson, S. (2015). Missnöjet pyr över svensk häktestortyr - En undersökning av det kritiserade häktningsinstitutet.
415. Ori, Y., & Solun, B. (2011). Severe hiccups associated with intra-articular corticosteroid injection — A case report. Open Medicine. https://doi.org/10.2478/s11536-011-0105-2
416. Ornoy, A. (2002). The effects of alcohol and illicit drugs on the human embryo and fetus.. PubMed.
417. Oslin, D. W. (2007). Addictions. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-960-8_9
418. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
419. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
420. Page, R. M. (2014). Substance Abuse and Adolescent Psychological Distress. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society. https://doi.org/10.1002/9781118410868.wbehibs433
421. Pais, S. C., Menezes, I., & Nunes, J. A. (2016). From Normative to Deviant Behaviour: Health and Illness Definitions Related to Children and Adolescents’ Perspectives. BRILL eBooks. https://doi.org/10.1163/9781848884885_004
422. Paraschakis, A., & Konstantinidou, D. (2012). P-664 - Stalking of psychiatrists by their patients: an unsettling reality. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74831-9
423. Parsa, A., Mohammadkhan, A., & Babaeian, M. (2017). Zolpidem-Induced Narcolepsy, Faint, Seizure or Coma? A Case Report. Case Reports in Clinical Medicine. https://doi.org/10.4236/crcm.2017.62004
424. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
425. Pattanashetti, L., & Doddanavar, A. (2022). Alcohol Induced Cerebellar Ataxia: A Case Report. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2022.14.25
426. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
427. Payne‐James, J., Perera, C., & Aggrawal, A. (2023). Neglect. CRC Press eBooks. https://doi.org/10.1201/9781003138754-54
428. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
429. Penn, M., & Goldstein, D. (2005). The Role of Hunger and Satiety in Weight Management. Humana Press eBooks. https://doi.org/10.1385/1-59259-865-x:307
430. Peprah, K., & McCormack, S. (2020). Ondansetron in Patients Requiring Anti-Emetics: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
431. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
432. Pergolizzi, J. V., Taylor, R. J., LeQuang, J. A., Gould, E. M., & Raffa, R. B. (2019). Treating Insomnia in Older Adult Patients: Limiting Benzodiazepine Use. Pharmacology &amp Pharmacy. https://doi.org/10.4236/pp.2019.103010
433. Perłowski, J., Miśkiewicz, M., Ptak, J., Noga, R., Teska, V., Marcinkowska, J., Herc, A., Koczkodon, K., Sawczuk, M., & Krompiewski, M. (2024). Recreational ketamine use and its impact on health. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.68.55185
434. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
435. Phan, S. V. (2016). Medication adherence in patients with schizophrenia. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217416636601
436. Phillips, M. M. (1990). The Alcohol Drinking History.
437. Pich, E. M., Heidbreder, C., Mugnaini, M., & Teneggi, V. (2003). Molecular and Behavioral Aspects of Nicotine Dependence and Reward. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_16
438. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
439. Polityńska, B., & Pelczar, M. (1998). [Pathogenesis and psychosocial consequences of post-concussion syndrome].. PubMed.
440. Pollack, M. H. (2001). Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder.. PubMed.
441. Powers, S. W., Gilman, D. K., & Hershey, A. D. (2006). Headache and Psychological Functioning in Children and Adolescents. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2006.00583.x
442. Prasad, S., Kumar, A., & Rajeswari, K. (2024). Episodic Bout of Shouting: A Rare Variant of Childhood Obsessive Compulsive Disorder (OCD). International Journal of Research and Review. https://doi.org/10.52403/ijrr.20240572
443. Prvčić, I., Zec, M. R., & Barišić, I. (2008). Psychological aspects of learning disabilities. Paediatria Croatica. https://doi.org/10.13112/pc.925
444. Pérez, I., & Lucas-Taracena, M. T. D. (2001). [Swallowing phobia: a case report].. PubMed.
445. Păunica, S., Giurgiu, M., Vasilache, A., Păunică, I., Motofei, I. G., Vasilache, A., Dumitriu, H., & Dumitriu, A. S. (2016). Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. https://doi.org/10.22543/2392-7674.1039
446. Płytycz, B., & Seljelid, R. (2002). Stress and immunity: minireview.. PubMed.
447. Queiroz, A. P. D. S., Pedro, M. O. P., Campos, M. W., Torales, J., Ventriglio, A., & Castaldelli-Maia, J. M. (2025). Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurology International. https://doi.org/10.3390/neurolint17070107
448. Rad, F., Anghel, C., Dobrescu, I., Buică, A., & Mihăilescu, I. (2017). ADHD from a multidisciplinary perspective. Psihiatru ro. https://doi.org/10.26416/psih.48.1.2017.1009
449. Rada, F. M., & Lucas-Taracena, M. T. D. (2006). [Swallowing phobia: symptoms, diagnosis and treatment].. PubMed.
450. Radhakrishnan, R., Wilkinson, S. T., & Dâ€TMSouza, D. C. (2014). Gone to Pot â€“ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00054
451. Rady, M. Y., & Verheijde, J. L. (2009). Continuous Deep Sedation Until Death: Palliation or Physician-Assisted Death?. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909109348868
452. Rajesh, M., & Kumar, C. P. G. (2014). Influence of interactional relationship on stress among women executives in software company in Chennai. EXCEL International Journal of Multidisciplinary Management Studies.
453. Rakofsky, J. J. (2016). RELAPSE: Answers to Why a Patient Is Having a New Mood Episode. Current psychiatry.
454. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
455. Ramakrishnan, N., Bansal, A., & Ponnish, A. S. (2022). Practical approach to sleep disordered breathing. Indian Journal of Respiratory Care. https://doi.org/10.5005/jp-journals-11010-02205
456. Ramos, B. R. M., Martins, F. S., & Osório, E. (2022). Psychotic Cannabis Withdrawal: A Clinical Case. Cureus. https://doi.org/10.7759/cureus.31465
457. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
458. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
459. Rao, M. G., Varambally, S., Venkatasubramanian, G., & Gangadhar, B. N. (2015). Hazards of antihistamine dependence in psychiatric patients: A case report. International Journal of Risk & Safety in Medicine. https://doi.org/10.3233/jrs-150656
460. Rao, S. (2016). Prolonged coma after anesthesia. Journal of Anaesthesiology Clinical Pharmacology. https://doi.org/10.4103/0970-9185.173339
461. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
462. Rastegar, D. A. (2020). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0009
463. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
464. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
465. Raymond, K. A. (2017). The Anger Quotient. SM Emergency Medicine and Critical Care. https://doi.org/10.36876/smem.1004
466. Reardon, C. L., & Benoy, R. (2023). Addiction (Drugs and Gambling) Disorders in Athletes. Routledge eBooks. https://doi.org/10.4324/9781003099345-12
467. Ree, J. M. V., Koob, G. F., Higgins, G. A., Naranjo, C. A., & Zvartau, E. (1995). Neurohormonal Systems Underlying Drug Addiction: Relevance for Treatment Strategies. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7218-8_27
468. Reed, D. D., & Naudé, G. P. (2020). Impulsivity and Self‐Control. The Encyclopedia of Child and Adolescent Development. https://doi.org/10.1002/9781119171492.wecad086
469. Riccio, C. A., Pliego, J., & Rae, W. A. (2016). Mind-body approaches and chronic illness: Status of research. International Journal of School & Educational Psychology. https://doi.org/10.1080/21683603.2016.1130544
470. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
471. Rj, T. (2002). [Complex visual hallucinations in partially sighted elderly: Charles Bonnet syndrome].. PubMed.
472. Roberts, J. R. (2016). InFocus. Emergency Medicine News. https://doi.org/10.1097/01.eem.0000476273.56614.28
473. Robertson, S., Peacock, E. E., & Scott, R. M. (2023). Benzodiazepine Use Disorder: Common Questions and Answers.. PubMed.
474. Robinson, T. E. (2014). Sensitization to Drugs.
475. Rodríguez, F. D., Sánchez, M. L., & Coveñas, R. (2023). Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108656
476. Roiser, J. P., & Husain, M. (2023). Apathy, Anhedonia and Fatigue. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.036
477. Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Façon, T., Leleu, X., Pasquier, F., & Rhun, É. L. (2013). Memory loss during lenalidomide treatment: a report on two cases. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-14-41
478. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
479. Rosen, D., Alcock, M., & Palmer, G. M. (2022). Opioids for acute pain management in children. Anaesthesia and Intensive Care. https://doi.org/10.1177/0310057x211065769
480. Rosli, A. (2017). Antidepressant Activity of Spirulina Platensis in Models of Depression. Psychology and Mental Health Care. https://doi.org/10.31579/2637-8892/003
481. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
482. Rowbotham, M. C., & Lowenstein, D. H. (1990). Neurologic Consequences of Cocaine Use. Annual Review of Medicine. https://doi.org/10.1146/annurev.me.41.020190.002221
483. ROY, R., Kumar, S. P., & Kishor, M. (2022). A Case of Trichotillomania With Comorbid Depression And Anxiety. Digital Journal of Clinical Medicine. https://doi.org/10.55691/2582-3868.1004
484. Rozanova, I. K., Petrovskaia, M. V., & Martynova, M. V. (2007). [Examination of personality and emotional-volitional disorders in the homeless with tuberculosis]..
485. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
486. Río, J. A. D. (2013). Incapacitación y drogodependencias.
487. Rösler, M., & Retz, W. (2007). Sozialmedizinische Aspekte der ADHS - Über die Ursachen und Folgen komorbider Störungen. psychoneuro. https://doi.org/10.1055/s-2007-993821
488. S.Suhasini (2015). Commentary on the Behavior Disorders in Children. Research and reviews: journal of nursing and health sciences.
489. Sadananda, P., Vahabi, B., & Drake, M. J. (2011). Bladder outlet physiology in the context of lower urinary tract dysfunction. Neurourology and Urodynamics. https://doi.org/10.1002/nau.21137
490. Saeed, S. A., & Tj, B. (1998). Panic disorder: effective treatment options.. PubMed.
491. Sanders, P. T., Cysyk, B. J., & Bare, M. A. (1996). Safety in Long-Term EEG/Video Monitoring. Journal of Neuroscience Nursing. https://doi.org/10.1097/01376517-199610000-00004
492. Santini, I., Lauretis, D., Roncone, R., Tosone, A., Bianchini, D’Onofrio, S., Ortenzi, R., Giusti, L., Casacchia, M., & Pollice, R. (2014). [Psychotropic-associated sexual dysfunctions: a survey of clinical pharmacology and medication-associated practice].. PubMed. https://doi.org/10.7417/ct.2014.1728
493. Sarkar, S. (2016). Psychiatric Polypharmacy, Etiology and Potential Consequences. Current Psychopharmacologye. https://doi.org/10.2174/2211556005666160916124719
494. Saunders, J. B. (2011). The Biology of Alcohol and Alcohol Misuse. https://doi.org/10.1002/9781118785089.ch4
495. Saunders, J. B., Sitharthan, T., & Krabman, P. (2001). An Overview of Substance Use Disorders and Their Management. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_132
496. Schneier, F. R., Bruce, L. C., & Heimberg, R. G. (2014). Social Anxiety Disorder (Social Phobia). American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg18
497. Schröder-Rosenstock, K., & Busch, H. (1996). [Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome].. PubMed.
498. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
499. Schwartz, R. H. (1984). Psychoactive Drug Use During Adolescence: The Pediatrician's Role. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1984.02140400083021
500. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
501. Schweren, L. (2016). Stimulants and the developing brain.
502. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
503. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
504. Segal, M. S. (2019). Cannabinoids and Analgesia. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-6
505. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
506. Sellers, E. M., Ciraulo, D. A., DuPont, R. L., Griffiths, R. R., Kosten, T. R., Romach, M. K., & Woody, G. (1993). Alprazolam and benzodiazepine dependence.. PubMed.
507. Shaikh, S., & Lakshmi, R. (2014). Delayed awakening after anaesthesia- A challenge for an anaesthesiologist. International Journal of Biomedical and Advance Research. https://doi.org/10.7439/ijbar.v5i8.829
508. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
509. Sharma, S., Nepal, B., Moon, C. S., Chabenne, A., Khogali, A., Ojo, C., Hong, E., Gaudet, R., Sayed-Ahmad, A., Jacob, A., Murtuza, M., & Firlit, M. L. (2014). Psychology of Craving. Open Journal of Medical Psychology. https://doi.org/10.4236/ojmp.2014.32015
510. Sharp, C. W., Rosenberg, N. L., & Beauvais, F. (2008). Substance Abuse: Inhalant‐Related Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch61
511. SheikhBahaei, S., Farhan, M., & Maguire, G. A. (2022). Improvement of stuttering after administration of methylphenidate - a case report. Personalized Medicine in Psychiatry. https://doi.org/10.1016/j.pmip.2022.100092
512. Sher, L. (2015). Parental alienation: the impact on men’s mental health. International Journal of Adolescent Medicine and Health. https://doi.org/10.1515/ijamh-2015-0083
513. Shields, L. B. E., Hunsaker, D. M., Hunsaker, J. C., Wetli, C. V., Hutchins, K. D., & Holmes, R. M. (2005). Atypical Autoerotic Death. American Journal of Forensic Medicine & Pathology. https://doi.org/10.1097/01.paf.0000153995.07817.9f
514. Shirley, K. L., Norelli, L. J., & Smith, H. S. (2008). “Impulsology” <i>A New Paradigm for Addiction</i>. https://doi.org/10.1093/oso/9780195300550.003.0013
515. Shoja, S., & Shafti, S. (2022). Appraisal of Abnormal Movement Disorders among Aged Schizophrenics: A Pilot Study. https://doi.org/10.31038/asmhs.2022633
516. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
517. Shulman, M., Greiner, M., & Bisaga, A. (2023). Commentary on Foot <i>et al</i>.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. Addiction. https://doi.org/10.1111/add.16374
518. Siedentopf, F., Horstkamp, B., Stief, G., & Kentenich, H. (1997). Clomiphene citrate as a possible cause of a psychotic reaction during infertility treatment. Human Reproduction. https://doi.org/10.1093/humrep/12.4.706
519. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
520. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
521. Singh, P. K. (2015). Psychogenic Headache in School Going Children. Indian Journal of Health and Wellbeing.
522. Siris, S. G. (1978). Use of Antidepressant Drugs in Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1978.01770350094009
523. Smith, A. D., & Aronson, J. K. (2002). Adverse reactions to drugs. https://doi.org/10.1093/oso/9780192632340.003.0009
524. Smith, K. M., Larive, L. L., & Romanelli, F. (2002). Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/59.11.1067
525. Smith, M. (2022). Addiction as a Sui Generis Force. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2022.13.00708
526. Smith, M. B. (2023). Addiction as a Sui Generis Force: An Opinion Overview. https://doi.org/10.9734/bpi/nramms/v3/6349a
527. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
528. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
529. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
530. Spier, S. A. (1995). Toxicity and Abuse of Prescribed Stimulants. The International Journal of Psychiatry in Medicine. https://doi.org/10.2190/kw49-885p-ea82-k6k3
531. Stanković, M., & Dostanic, N. (2007). Psychotic epizode of multiple drug user after acute anticholinergic intoxication - a case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.1012
532. Stanković, M., Dostanic, N., Sarajlija, M., & Vujošević, A. (2007). Psychotic episode of multiple drug user after acute anticholinergic intoxication: A case report. Engrami.
533. Stearns, M., McCrae, C. S., Curtis, A., Nair, N., Hayse, B., Nadorff, D., & Wilkerson, A. K. (2024). Adolescent sleep mediates maternal depressive problems and parenting behaviors: daughter and son differences in a majority Black and Hispanic sample. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10996
534. Steininger, S. C., Frizi-Roser, R., Schneider, S., Hoang, T., & Zetzsche, D. A. (2024). Underrated and Underestimated – Deprivation in Dementia. A Case Report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1321
535. Stewart, J. (2003). Stress and Relapse to Drug Seeking: Studies in Laboratory Animals Shed Light on Mechanisms and Sources of Long‐Term Vulnerability. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00535.x
536. Stibolt, O., & Wachowiak‐Andersen, G. (2002). Altered response to intravenous thiopental and succinylcholine in acute amphetamine abuse. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1034/j.1399-6576.2002.460522.x
537. Stohler, R., Rommelspacher, H., Ladewig, D., & Dammann, G. (1993). [Beta-carbolines (harman/norharman) are increased in heroin dependent patients].. PubMed.
538. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
539. Strassnig, M., & Harvey, P. D. (2013). Treatment of obesity and disability in schizophrenia.. PubMed.
540. Stratakis, C. A., Gold, P. W., & Chrousos, G. P. (1995). Neuroendocrinology of Stress: Implications for Growth and Development. Hormone Research. https://doi.org/10.1159/000184269
541. Stringer, J. D. (2016). Gender and Sexual Health: Sexual Dysfunction.. PubMed.
542. Strosahl, K. D. (2022). ACT con el paciente multiproblemático. ABA España eBooks. https://doi.org/10.26741/978-84-09-43990-4_09
543. Suetendael, L. V., Schrijvers, T., Broeck, K. V. D., Michielsen, J., Dom, G., & Destoop, M. (2024). [Police and judicial actors on complex mental health care needs and judicial protection measures].. PubMed.
544. Sullivan, M. A., & RUDNIK‐LEVIN, F. (2001). Attention Deficit/Hyperactivity Disorder and Substance Abuse. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb05783.x
545. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
546. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
547. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
548. Sussman, S. (2025). Vulnerability to addictive behaviors: the Associational Memory‐Appetitive Systems Relations Model. World Psychiatry. https://doi.org/10.1002/wps.21283
549. Sussman, S., & Ames, S. L. (2008). Concepts of Cessation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511500039.016
550. Swash, M., & Schwartz, M. A. (1988). Miscellaneous Disorders. Neuromuscular Diseases. https://doi.org/10.1007/978-1-4471-3526-5_21
551. Talambas, S., Amaral, M. J., Vieira, A., Rodrigues, M., & Manzano, M. N. S. (2022). Impacto Laboral da Perturbação Obsessivo-Compulsiva: Caso Clínico. Revista Portuguesa de Saúde Ocupacional. https://doi.org/10.31252/rpso.12.02.2022
552. Tariq, F. (2012). Premature Ejaculation Re-Visited: Definition and Contemporary Management Approaches. InTech eBooks. https://doi.org/10.5772/25670
553. Taylor, G. J. (1997). Treatment considerations. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511526831.014
554. Teicher, M. H., Cohen, B. M., Baldessarini, R. J., & Cole, J. O. (1988). Severe daytime somnolence in patients treated with an MAOI. American Journal of Psychiatry. https://doi.org/10.1176/ajp.145.12.1552
555. Tikhonenko, V., & Dmitrieva, T. (2002). The Concept of Rehabilitation in Borderline Psychiatry. International Journal of Mental Health. https://doi.org/10.1080/00207411.2002.11449549
556. Tiwari, M. S. K., & Kushwaha, M. M. D. (2022). Adverse Effect of Non-Narcotic Drug on CNS and Visceral Organ. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-3081
557. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
558. Tollefson, G. D., Rampey, A. H., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W. K., & Genduso, L. A. (2022). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203822937-24
559. Tollefson, G. D., Souêtre, E., Thomander, L., & Potvin, J. H. (1993). Comorbid anxious signs and symptoms in major depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199300840-00013
560. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
561. Torres, A. R., & Smaira, S. I. (2001). Quadro clínico do transtorno obsessivo-compulsivo. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462001000600003
562. Touze, M.-D., Potel, G., & Baron, D. (1993). [Acute ethyl alcohol intoxication].. PubMed.
563. Tranel, D., McNutt, A., & Bechara, A. (2012). Smoking Cessation After Brain Damage Does Not Lead to Increased Depression. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0b013e3182492a9c
564. Trujillo, K. A. (2002). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_20
565. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
566. Turki, T. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report. Journal of King Abdulaziz University-Medical Sciences. https://doi.org/10.4197/med.10-1.12
567. Turki, T. A. A., & Arabia, S. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report.
568. Tworowska, U., & Medraś, M. (2001). [Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids].. PubMed.
569. Tyler, R. E., & Leggio, L. (2024). Biological basis of addiction and alcohol use disorder. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000177
570. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
571. Ullah, I., & Jamil, M. I. (2023). Interstitial Cystitis/Bladder Pain Syndrome. IntechOpen eBooks. https://doi.org/10.5772/intechopen.111676
572. Upadhyay, S., Elmatite, W., Taqi, S., Jagia, M., & Mallick, P. (2011). Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian Journal of Palliative Care. https://doi.org/10.4103/0973-1075.92353
573. Ursano, R. J., & Rundell, J. R. (1990). The Prisoner of War. Military Medicine. https://doi.org/10.1093/milmed/155.4.176
574. Vaisrub, S. (1978). Cushing's Syndrome—Still a Conundrum. JAMA. https://doi.org/10.1001/jama.1978.03290090059024
575. Valdez, J. M. (2013). [Status epilepticus in childhood].. PubMed.
576. Vancleef, L. M. (2007). At risk for pain : pain-related anxiety, cognition, and processing biases. https://doi.org/10.26481/dis.20071108lv
577. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
578. Vasile, D., & Vasiliu, O. (2022). Orthorexia nervosa – a different lifestyle or a specific eating disorder?. Psihiatru ro. https://doi.org/10.26416/psih.68.1.2022.6300
579. Vaswani, M. (2023). Addiction Dispelling Myths. https://doi.org/10.37871/jbres1786
580. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
581. Vergauwen, K. (2024). Physical activity, participation and health-related quality of life in chronic fatigue syndrome and multiple osteochondromas. https://doi.org/10.26481/dis.20240425kv
582. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
583. Verrips, A., Diagos, P., Bos, J. A. G., & Booij, L. (2003). Giant axonal neuropathy and anaesthesia. Anaesthesia. https://doi.org/10.1046/j.1365-2044.2003.327915.x
584. Večeř, J., Kubátová, H., Charvát, J., Souček, M., & Kvapil, M. (2001). [Ethylene glycol poisoning].. PubMed.
585. Viel, É., Pélissier, J., Enjalbert, M., Kotzki, N., & Eledjam, J. (1993). [Chemical neurolysis using alcohol (alcoholization) in the treatment of spasticity in the hemiplegic].. PubMed.
586. Vignau, J., & Karila, L. (2003). [Substance abuse in adolescents].. PubMed.
587. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
588. Vitale, C., Trojano, L., Barone, P., Errico, D., Agosti, V., Sorrentino, G., Grossi, D., & Santangelo, G. (2013). Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.. PubMed. https://doi.org/10.3233/ben-129024
589. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
590. Vogel, S. L. (2001). Urinary incontinence in the elderly.. PubMed.
591. Voon, V., Thomsen, T., Miyasaki, J. M., Souza, M. D., Shafro, A., Fox, S. H., Duff‐Canning, S., Lang, A. E., & Zurowski, M. (2007). Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.64.2.212
592. Vos, C. F., Zaal, I. J., Pop‐Purceleanu, M., & Boogaard, M. V. D. (2023). [Prevention of delirium in the Intensive Care Unit].. PubMed.
593. Vos, M. S., & Berendsen, H. H. (2001). ['Doctor, I don't want to know that'--exploring denial in patients with lung cancer].. PubMed.
594. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
595. Wada, S., Iwamoto, K., & Ikeda, M. (2025). IMPACT OF ANTIPSYCHOTICS ON PROLACTIN LEVELS IN PEDIATRIC AND ADOLESCENT PATIENTS WITH PSYCHIATRIC DISORDERS IN REAL-WORLD PSYCHIATRIC CLINICAL PRACTICE. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.612
596. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
597. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
598. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
599. Wang, S. (2001). Analysis on the 30 Cases of the Mental Barriers Caused by Taking Some Anti-psychosis Drugs. Journal of Inner Mongolia University for Nationalities.
600. Wdowiak, K., Maciocha, A., Julia, Witas, A., Drogoń, J., Chachaj, W., Słomka, P., Gwóźdź, E., Konieczko, D., & Gardocka, E. (2024). issue of recreational use of sildenafil. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.66.55563
601. Weaver, M. F., Heads, A. M., & Faillace, L. A. (2024). Mood Disorders and Comorbid Substance Use Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.013
602. Wesson, D. R., Smith, D. E., Ling, W., & Sabnani, S. (2008). Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch64
603. Wheeler, S. (2014). Approaches to Managing Executive Cognitive Functioning Impairment Following TBI: A Focus on Facilitating Community Participation. InTech eBooks. https://doi.org/10.5772/57395
604. White, D. M., Daniell, W., Maxwell, J. K., & Townes, B. D. (1990). Psychosis following styrene exposure: A case report of neuropsychological sequelae. Journal of clinical and experimental neuropsychology. https://doi.org/10.1080/01688639008401020
605. Wick, J. Y., & Zanni, G. R. (2011). Helping Those with Hoarding Behaviors. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2011.458
606. Wieser, T., Walliser, U., Womastek, I., & Kress, H. G. (2011). Dysfunctional coping in headache: Avoidance and endurance is not associated with chronic forms of headache. European Journal of Pain. https://doi.org/10.1016/j.ejpain.2011.06.011
607. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
608. Winner, P., Hershey, A. D., & Li, Z. (2007). Headaches in Children. https://doi.org/10.1093/oso/9780195326567.003.0027
609. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
610. Wise, R. A. (1982). Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x00010372
611. Wolf, P., Lin, K., Mameniškienė, R., & Walz, R. (2020). Does Epilepsy Have an Impact on Locus of Control?. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2020.02251
612. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
613. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
614. Yennurajalingam, S., & Bruera, É. (2015). Fatigue and asthenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199656097.003.0081
615. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
616. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
617. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
618. Zaman, M., Aljeshi, A., Kuraga, K., Bunni, S., Sarker, T., Kashif, A. W., Sathish, J., Abouzeid, H., Alouf, H., Chinthamraks, J., Krishnan, A., Patker, S., Talreja, S., & Pentapati, D. (2025). Recreational Drugs Addiction, Withdrawal and its Impact on the body: A Literature Review. Medical Research Archives. https://doi.org/10.18103/mra.v13i3.6295
619. Zawilska, J. B., & Tomaszewska, A. (2019). Psychoactive substances used to increase sexual activity: chemsex. Farmacja Polska. https://doi.org/10.32383/farmpol/116296
620. Zhang, Z., Greenberg, A. S., Rose, L., Jayasooriya, T., Thomas, N., & Das, S. (2025). A case of depression with psychotic features associated with hemoglobin Manukau mutation. Psychiatry and Clinical Neurosciences Reports. https://doi.org/10.1002/pcn5.70145
621. Zhao, J., & Tomm, B. M. (2016). Psychological Responses to Scarcity. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.41
622. Zoorob, R., Kowalchuk, A., & Grubb, M. D. (2018). Buprenorphine Therapy for Opioid Use Disorder.. PubMed.
623. Zulkifli, N., Khuzaini, A. M., Aziz, A. A., & Awang, H. (2023). Trauma-related hallucination in an 8-year-old child with dissociative symptoms. Deleted Journal. https://doi.org/10.4103/mjp.mjp_10_23
624. Zwaan, S. V. D., Blankespoor, R. J., Wolters, A. M. H., Creten, C., Leroy, P., & Schieveld, J. N. M. (2011). Additional use of methotrimeprazine for treating refractory agitation in pediatric patients. Intensive Care Medicine. https://doi.org/10.1007/s00134-011-2414-y
625. Özten, M., & Erol, A. (2013). Fluoxetine Induced Hypomanic Shift in a Bulimic Patient: Case Report. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20130112010027
626. Şengül, C., Özen, M., & Sunumu, O. (2010). Do Münchausen syndrome or malingering.